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ABSTRACT
Brown, Jessica Marlene. Evaluation of the Phase Training Model of Cancer
Rehabilitation. Published Doctor of Philosophy dissertation, University of
Northern Colorado, 2016.

Exercise is a well-established method of alleviating cancer-related toxicities
during and following treatment in cancer survivors. Due to this clear evidence, exercisebased rehabilitation programs have begun to emerge. Of concern, specific
recommendations of exercise prescription for patients at different time points on the
cancer continuum have not been developed, and available guidelines are broad and
unclear. The Phase Training Model of cancer rehabilitation was created to address this
issue and replace our previously used method of exercise-based prescription and
intervention. Purpose: To evaluate the effects of the Phase Training Model on
cardiorespiratory endurance, muscular strength (MS), and cancer-related fatigue (CRF) in
cancer survivors during the transition from each Phase and in those who have completed
the entire Phase Training Model. Methods: A total of 152 cancer survivors’ data were
utilized. The Phase Training Model consists of four sequential Phases representing
differing time points from treatment. The designated Phase prescribes intensity,
progression, and goals unique to each. Changes in peak volume of oxygen consumption
(VO2peak), chest press MS, leg press MS, and CRF were observed in transitions from
Phase 1 to 2, Phase 2 to 3, and Phase 3 to 4. Absolute values and percent change of
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VO2peak from data collected in the previous version of the program were compared to the
data collected in the Phase Training Model. Results: VO2peak, chest press MS, leg press
MS, and CRF all significantly improved from Phase 1 to Phase 2, and from Phase 2 to
Phase 3 (p < 0.05). VO2peak and chest press MS significantly improved in patients
transitioning from Phase 3 to 4 (p < 0.05). VO2peak improved to a greater extent in the
Phase Training Model when compared to the previous program (29.4% and 14.8%,
respectively. Conclusion: These findings suggest the Phase Training Model provides the
first clear and reproducible guidelines for exercise prescription in cancer survivors, and is
more effective at improving cardiorespiratory endurance than the previous model of the
program. This model of exercise-based intervention yielded significant physiological and
psychological improvements in patients both during and immediately following
treatment, with reduced results as time from treatment increases.
Keywords: cancer, cancer rehabilitation, oncology rehabilitation, exercise-based
interventions
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CHAPTER I

INTRODUCTION
Cancer is a disease that is characterized by abnormal and uncontrolled cell
growth. Currently, there are 14.5 million Americans with a history of cancer, and
1,658,370 new diagnoses are expected to be made in 2015 (American Cancer Society,
2015). The gerontological population has the greatest risk of developing cancer as 78%
of cancer diagnoses affect those who are 55 years of age or older (ACS, 2015). Males
have the greatest risk of developing cancer, with a slightly less than 50% chance, while
females have approximately a 33% risk (ACS, 2015). About 590,000 Americans are
expected to die from cancer this year. Fortunately, the 5-year survival rate for all cancers
between 2004 and 2010 is now at 68%, which is substantially higher than the 49%
survival rate between 1975-1977 (ACS, 2015). This increase in survival rate may be due
to earlier detection, prevention, and the advanced cancer treatments now available.
Advancements in cancer treatments such as chemotherapy and radiation have
increased survival rates of cancer patients, but often result in many deleterious sideeffects during and following treatments. Cancer survivors can suffer from physiological
toxicities affecting the following systems: cardiovascular, pulmonary, musculoskeletal,
immune, gastrointestinal, hepatic, and neuroendocrine (Schneider, Dennehy, & Carter,
2003; Schneider, Dennehy, Roozeboom, & Carter, 2002). Additionally, many survivors
will experience psychological decrements such as increased fatigue
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(Daniell, 2004; Stone & Minton, 2008; Wu & McSweeney, 2007), increased depression
(Dauchy, Dolbeault, & Reich, 2013; Gagliese, Gauthier, & Rodin, 2007; Ng, Boks,
Zainal, & de Wit, 2011), and decreased quality of life (QOL) (Lee et al., 2010; Rauma,
Sintonen, Räsänen, Salo, & Ilonen, 2015).
In 1971, the National Cancer Act was established to investigate the rehabilitative
needs and evaluate interventions established for cancer survivors to improve diagnosis,
treatment, and care delivery. From this, rehabilitation programs began to emerge for
cancer survivors (Lehmann et al., 1978) and from 1971 to the late 1990’s, these programs
consisted of large, hospital-based multidisciplinary approaches utilizing oncologists,
social workers, surgeons, physical therapists, and other healthcare professionals. This
remained the only model of rehabilitation for cancer survivors until the advent of exercise
only-based rehabilitative interventions (DeLisa, 2001; Schneider et al., 2002). The
opportunity to move towards a single mode of intervention— exercise—instead of the
numerous therapies seen with most multidisciplinary approaches stemmed from the
advancements in cancer care that have occurred within the last 30 years. Advances in
detection, diagnosis, and treatments have improved prognosis and lessened the need for
hospital and physician-based interventions (Alfano, Ganz, Rowland, & Hahn, 2012).
Exercise-based programs are a viable option of cancer rehabilitation for cancer survivors
as the benefits of exercise directly attenuate the toxicities and decrements of cancer and
concurrent treatments (Dittus et al., 2015; Schmitz et al., 2010; Schneider et al., 2002). It
has been demonstrated throughout the literature that cancer survivors who perform
physical activity before, during, and/or after treatments have significant improvements in
muscular strength, maximal oxygen consumption, flexibility, and QOL, as well as
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decreased levels of fatigue and depression (Herrero et al., 2006; Schneider, Hsieh, Sprod,
Carter, & Hayward, 2007a). As the benefits of physical activity on cancer recovery is
gaining recognition from oncologists and physicians, more cancer survivors are now
being exposed to exercise-based rehabilitation services (Thorsen et al., 2011).
Exercise-based interventions should be comprehensive and address the
multidimensional needs of cancer survivors during treatment and following treatment.
For this reason, a “one size fits all” approach to exercise interventions will not suffice
(Marcus et al., 2000), and survivors need prescriptive exercise that is specialized for each
individual based on treatment status and placement on the cancer continuum. The cancer
continuum commonly refers to the various points of cancer survivorship, from
prevention, to detection and diagnosis, treatment, survivorship, and end of life (National
Cancer Institute, 2011). Organizations and facilities that are offering exercise-based
cancer rehabilitation are starting to emerge, and many of them are not located or affiliated
with a hospital or medical organization. Of note, there are many different modes and
intensities that are being used for physical activity-based interventions in the cancer
population, and most are unstructured. To date, there is only one longstanding model of a
standardized exercise intervention with guidelines for intensity, frequency, and duration
for cancer survivors (Schneider et al., 2003; Schneider et al., 2002). Evidence that this
program improves cardiovascular endurance, muscular endurance, and reduces fatigue
has been well documented following a 6-month intervention (Schneider et al., 2002;
Schneider, Hsieh, Sprod, Carter, & Hayward, 2007b; Schneider, 2013); however, further
analysis of this program suggests reduced improvements with continued exercise, while
physical functioning remains well below average (Brown, Lalonde, Dallow, Hayward, &
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Schneider, 2012) . It was concluded that this prescriptive exercise intervention was
sufficient to improve cancer survivor’s physiological function at the onset, but suggests
that survivors may begin to experience diminishing returns from exercise training as the
program lengthens. For those working with cancer survivors, greater attention should be
paid to the principles of exercise training, specifically progression and overload to ensure
that these individuals continue to improve and reach apparently healthy status. To this
purpose, creation of a new model of exercise-based cancer rehabilitation is needed to
ensure patients continue to improve physiological and psychological functioning
throughout the rehabilitation program. Revision of previous recommendations of
intensity, duration, and frequency are needed and guidelines should be established for
each patient based on treatment status and placement on the cancer continuum. The
University of Northern Colorado Cancer Rehabilitation Institute (UNCCRI) has created a
Phase Training Model to address these issues and concerns. The effectiveness of this
model must be evaluated.
Statement of Purpose
The purpose of this study is to evaluate the effects of the Phase Training Model
on cardiorespiratory endurance, muscular strength, and cancer-related fatigue in cancer
survivors during the transition from each Phase and in those who have completed the
entire Phase Training Model.
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Research Hypotheses
H1

Cancer survivors transitioning from Phase 1 to Phase 2 of the Phase
Training Model will significantly increase cardiovascular endurance,
muscular strength, and decrease levels of fatigue.

H2

Cancer survivors transitioning from Phase 2 to Phase 3 of the Phase
Training Model will significantly increase cardiovascular endurance,
muscular strength, and decrease levels of fatigue.

H3

Cancer survivors transitioning from Phase 3 to Phase 4 of the Phase
Training Model will increase cardiovascular endurance and muscular
strength, and these improvements will yield classifications representing
apparently healthy status. Values for fatigue will improve yielding a
normal classification.

H4

Cancer survivors who complete the entire Phase Training Model (from
entry to Phase 4) will maintain or improve values of cardiovascular
endurance and muscular strength.

H5

Improvements observed in cardiovascular endurance will be greatest for
those subjects who complete the Phase Training Model (from entry to
Phase 4) compared with subjects who participated in the previous version
of the program for an equivalent period of time.

Significance of Study
Exercise is a well-established method of alleviating cancer-related toxicities
during and following treatment in cancer survivors (Brown, Huedo-Medina, et al., 2012;
Murtezani et al., 2014; Schneider et al., 2007a). Specifically, exercise interventions
attenuate cardiotoxicity (Arola et al., 2000; Eschenhagen et al., 2011; Richard et al.,
2011), pulmonary toxicity (Camp-Sorrell, 2006; Ohe, 2002) , musculoskeletal
dysfunction (Barret et al., 2014; Tisdale, 2009), and myelosuppression (Rasmussen &
Arvin, 1982; Schneider et al., 2003). Due to the clear evidence that exercise plays an
integral role in cancer survivorship, exercise–based cancer rehabilitation programs have
begun to emerge. Of concern, most exercise programs to date have failed to properly
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apply and adhere to the principles of exercise training: individuality, specificity,
progression and overload (referred to as progressive overload), reversibility, and
diminishing returns (Campbell, Neil, & Winters-Stone, 2012; Kenney, Wilmore, &
Costill, 2015). Subsequently, these interventions violate standards that must be employed
to prescribe the appropriate dosage and mode of exercise to ensure optimal and
reproducible results.
The American College of Sports Medicine (ACSM) suggests cancer survivors
reach at least 150 minutes of moderate physical activity or 75 minutes of vigorous
activity per week (American College of Sports Medicine, 2013). However, these
guidelines are very broad and are not specific enough for cancer survivors. Furthermore,
it is currently unclear how to alter exercise prescriptions for patients at different time
points on the cancer continuum, as well as why or when to modify exercise dosage during
an intervention to elicit specific adaptations. The Phase Training Model of cancer
rehabilitation was created to address these concerns and provide a clear method of
exercise prescription and intervention to alleviate treatment-related toxicities. Therefore,
this study is focused on evaluating the effectiveness of the Phase Training Model on
physiological and psychological function in cancer survivors.
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CHAPTER II

REVIEW OF LITERATURE
Introduction
Cancer is the second leading cause of death in the United States, only succeeded
by heart disease, but is now the leading cause of death in 21 US states (American Cancer
Society, 2015; Siegel, Miller, & Jemal, 2015). Unfortunately, more than half a million
Americans are expected to succumb to cancer, with more than 1,600 deaths attributed to
the disease per day (ACS, 2015). Cancer can affect any organ or part of the body, with
breast and prostate cancers representing the largest majority in males and females,
respectively. However, lung and bronchus cancer are the deadliest and account for the
most deaths (ACS, 2015). Although cancer is a leading cause of death in the United
States, the 5-year survival rate for all cancers is improving. The survival rates for those
diagnosed between 2004-2010 was 68%, which is 19% higher than the survival rates seen
between 1975-1977 (ACS, 2015). This increase in survivability may be attributed to
earlier detection and advancements in cancer treatments. Despite the increased
prognosis, cancer survivors still suffer from debilitating treatment-related toxicities.
Specifically, the side effects associated with cancer and its concurrent treatments result in
serious decrements in physiological and psychological function, represented by decreased
VO2peak, pulmonary function, muscular strength, myelosuppression, and increased
fatigue, depression, and ultimately a reduction in QOL. Due to this, establishing a
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standard cancer rehabilitation program to properly address these variables is needed.
Cancer rehabilitation may consist of many aspects such as: nutritional planning, social
support groups, art therapy, stress management, massage, acupuncture, occupational
therapy, and/or educational services (Gudbergsson et al., 2015; Silver et al., 2015).
While several modes are utilized, exercise-based interventions remain a well-established,
documented and effective method of rehabilitation for cancer survivors (Courneya, 2003;
Schmitz et al., 2010; Schneider et al., 2002; Warburton, Nicol, & Bredin, 2006). Despite
this knowledge, precise exercise prescription and standardization of exercise-based
models has not been developed (Brown, Lalonde, et al., 2012; Winters-Stone, Neil, &
Campbell, 2013).
Cancer Treatments
Advancements of cancer treatments is one of the primary contributing factors
leading to the overall increases in survivorship. There are many treatment options
available, however the most effective and common treatments include chemotherapy,
radiation, and surgery. Other treatments can include, but are not limited to, hormonal
treatment, immunotherapy, hyperthermia treatment, and stem cell transplants (ACS,
2015). These treatments are not as regularly used but may still be effective in the
appropriate circumstance, such as when treating a specific cancer type.
Chemotherapy is one of the most effective forms of cancer treatment. It is usually
administered by infusion via vein or artery allowing it to affect the entire body
systemically. In other cases it might be taken orally via a pill or liquid, or it may be
absorbed into the skin as a cream (Sugerman, 2013). These types of drugs attempt to kill
the cancer cells directly, stop the cancer from spreading, and/or slow the rate of growth of
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tumors. There are different classes of chemotherapy, each having its own unique
mechanism in treating cancer. The most common classes of chemotherapy are alkylating
agents, antimetabolties, antitumor antibiotics, and alkaloids (Schneider et al., 2003).
Alkylating agents bind with the DNA in DNA synthesis to stop cell replication.
Antimetabolites attack the cancer cells during mitosis, and will imitate normal cell
nutrients in order to starve the cancer cell. Antitumor antibiotics are inserted in the
strands of DNA, inhibiting the synthesis of RNA. Finally, alkaloids inhibit cell
replication by interrupting the formation of chromosomes (Schneider et al., 2002).
Although chemotherapy is very effective at interfering with cancerous cell growth, it is
also extremely cytoxic to healthy cells, resulting in the most severe toxicities. These
side-effects affect both physiological and psychological function, leading to
cardiovascular, pulmonary, musculoskeletal, and immune toxicities, while increasing
fatigue, depression, and reducing QOL (Carayol et al., 2013; Chap et al., 1997;
Curigliano et al., 2012; Dauchy et al., 2013; Schneider et al., 2002).
Radiation therapy uses high energy x-rays, electron beams, or radioactive
isotopes to damage or destroy malignant cancer cells (Schneider et al., 2003). However,
like chemotherapy, it will affect normal cells surrounding the cancerous tumor.
Typically, radiation is used to target small, localized tumors and is not used in metastatic
cancers, where a systemic treatment is needed (Schneider et al., 2003). There are
different types of radiation, with internal and external representing the two most
common. External beam radiation aims the beams of energy from a source outside of the
body at the target site of cancer. Internal radiation surgically places a radioactive isotope
directly on or near the tumor inside of the body. Administration of radiotherapy will also
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result in side effects, such as necrosis, fibrosis, ulcerations, irritations of the skin, damage
to the specific organs where the radiation was administered, increased fatigue, decreased
QOL, and increased depression (Schneider et al., 2003; Whelan, Levine, Julian,
Kirkbride, & Skingley, 2000).
Surgery is one of the most effective methods of treatment for eliminating cancer
from the body. If the tumor is small and confined to one area, it may be completely
removed along with some normal surrounding tissue. If the tumor is larger and cannot be
removed in its entirety, debulking, or removing part of the tumor gives adjuvant
treatment a better chance at eliminating the cancer cells (Schneider et al., 2003). Besides
removal of cancerous cells, surgery can be used as a diagnostic tool and a preventive
measure. By obtaining a biopsy, medical staff are able to determine the tumor grade and
cancer stage. If an individual does not yet have cancer but are positive for a gene or loss
of a gene, such as BRCA1, they may opt to have preventive surgery and remove the
entire breast to eliminate any risk of developing cancer. Surgery is very effective for
localized tumors and causes few side effects beyond pain, decreased range of motion at
the incision site, and lymphedema (Schneider et al., 2003).
Side Effects from Cancer Treatments
Cancer survivors experience a vast array of concurrent physiological and
psychological side effects which may affect any organ or system in the body. The
decrements are complex and variable between patients, even those with the same cancer
diagnosis or treatment regimen. The toxicities experienced can manifest in the
cardiovascular, pulmonary, musculoskeletal, and immune systems, and can lead to
fatigue, depression, and reduced QOL.

11

Cardiovascular Toxicity
Chemotherapeutic agents can directly damage the heart and can lead to cardiac
dysfunction (Schneider et al., 2003; Yeh et al., 2004). Anthracyclines such as
doxorubicin have been reported to result in cardiotoxicity after repeated bouts of dosedependent administration, which may play a role in the disruption of myofibrils and
contractile proteins, cardiomyocyte apoptosis, and oxidative stress (Eschenhagen et al.,
2011; Richard et al., 2011). Repeated cycles of chemotherapy may lead to cardiotoxicity
months or even years after treatment, however acute cardiotoxicity can take place
minutes after administration (Arola et al., 2000; Monsuez, Charniot, Vignat, & Artigou,
2010; Shakir & Rasul, 2009; Vejpongsa & Yeh, 2014). Cardiotoxicities may develop
into congestive heart failure or cardiomyopathy once treatment is finished (Monsuez et
al., 2010; Wood, Shapiro, & Recht, 2001). Radiation treatments may also result in
similar side effects. External radiation to the thoracic region may damage the
myocardium, pericardium, valves, and coronary vessels (Veinot & Edwards, 1996).
Radiation may cause fibrous thickening of the pericardium, commonly resulting in
pericarditis (Veinot & Edwards, 1996). Valvular heart disease is a common side effect
due to the thickening of the cardiac valves (Veinot & Edwards, 1996). Additionally,
patients may also experience complications such as angina, dyspnea, and in extreme
cases, sudden death (Brosius, Waller, & Roberts, 1981).
Pulmonary Toxicity
Cancer survivors who are undergoing cancer treatments experience both acute and
chronic pulmonary side-effects, which may develop within days or possibly years after
treatment. Chemotherapy will initially damage the endothelial cells, which may result in
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an inflammatory response leading to drug-induced pneumonitis and pulmonary fibrosis
(Camp-Sorrell, 2006). In some instances, the interstitial pneumonitis can progress to
fatal pulmonary fibrosis if it is left untreated (Ohe, 2002; Pavlakis, Bell, Millward, &
Levi, 1997; Peters et al., 1993). Chemotherapy can also cause detrimental alterations to
the pulmonary parenchyma, connective tissue, and alveoli (Camp-Sorrell, 2006).
Radiation treatments to the thoracic area can produce comparable toxicities as well, such
as pneumonitis and fibrosis. Radiation can also destroy the cell lining of the alveoli,
causing inflammation. These effects will depend on the volume of the lungs that are
irradiated and the radiation dose (Villani et al., 1997), and greater cumulative doses of
radiation result in a higher risk of radiation pneumonitis (Mehta, 2005). In fact, it is
estimated that roughly 10-20% of patients receiving chemotherapy or radiotherapy will
suffer from severe pneumonitis (Mehta, 2005). This ultimately will lead to impaired
diffusion of oxygen and carbon dioxide within the alveoli (Abid, Malhotra, & Perry,
2001), shortness of breath, low functional capacity, and dyspnea (Schneider et al., 2002).
Musculoskeletal Alterations and Decrements
Muscular degeneration is another common side-effect observed in cancer
survivors, with approximately 50% of patients experiencing some type of muscle wasting
(Tisdale, 2009). Cancer cachexia, or the involuntary loss of muscle and adipose tissue as
a result of cancer and the associated treatments, results from a decrease in protein
synthesis and an increase in protein degradation. The decrease in protein synthesis may
be attributed to a reduced level of initiation factor 4F and elongation factor 2, while an
increase in protein degradation results from increased activity of the ubiquitinproteasome pathway and lysosomes (Tisdale, 2009). Additionally, tumor and host factors
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such as proteolysis-inducing factors, tumor necrosis factor-α, pro-inflammatory
cytokines, and angiotensin II may result in muscle wasting (Gordon, Green, & Goggin,
2005; Tisdale, 2009). The wasting of skeletal muscle will contribute to a decrease in
muscular strength, as muscle mass is directly proportional to muscular strength (Jones,
Rutherford, & Parker, 1989; Stewart, Skipworth, & Fearon, 2006). Chemotherapy
treatment is the largest contributing factor that worsens the effects of cachexia and the
loss of muscle mass (Barret et al., 2014; Braun et al., 2014; Jung et al., 2015; Miyamoto
et al., 2015; Sjøblom et al., 2015) and contributes to the decrease in overall strength
observed in cancer survivors (Kilgour et al., 2010; Merchant, Chapman, Kilbreath,
Refshauge, & Krupa, 2008; Salhi et al., 2014). Radiation will also negatively alter
skeletal muscle, as it may alter the sarcolemma, sarcoplasmic reticulum, and
mitochondrial membrane, which will lead to altered force generation. Similarly,
myofibrils and myofilaments will be damaged and become disorganized due to
radiotherapy, leading to decreased force production (Schneider et al., 2003).
Immune System Toxicity
Cancer treatments negatively affect the immune system and may result in
myelosuppression, or the decrease in production of immune cells in the bone marrow.
Specifically, immune system toxicity can lead to leukopenia, lymphocytopenia,
granulocytopenia, and thrombocytopenia (Rasmussen & Arvin, 1982; Schneider et al.,
2003; Schwartz, 1968). Chemotherapy-induced neutropenia is a common side effect of
myelosuppression and often results in hospitalization (Lyman, Abella, & Pettengell,
2014). Suppressed immune function is a common, treatment-related, chronic side-effect
of radiation, and is associated with early death from tumor progression (Grossman et al.,
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2011). The overall extent of cell death and myelosuppression will depend on the type,
dose, and location of the cancer treatment (DeVita, Hellman, & Rosenberg, 1997; Kohn
& Melvold, 1976). Immune system toxicity results in an increased susceptibility to
infections and diseases and in rare cases, more serious diseases such as pneumonia and
premature death (Schneider et al., 2002).
Fatigue
Cancer-related fatigue (CRF) is the most prevalent side-effect experienced by
cancer survivors during and following treatment (Hofman et al., 2004; Hofman, Ryan,
Figueroa-Moseley, Jean-Pierre, & Morrow, 2007). CRF is described as an
overwhelming, draining, whole-body tiredness that is unrelated to activity or exertion,
and negatively impacts overall well-being and activities of daily living. CRF is not
alleviated by rest and may be augmented by sedentary behavior (Schneider et al., 2003;
Wu & McSweeney, 2007). Stedman’s medical dictionary further describes fatigue as a
state when ATP expenditure outstrips the restorative processes of the body (Lewis, 2000).
CRF may result from cardiotoxicity, pulmonary toxicity, musculoskeletal toxicity, and
other physiological toxicities resulting from treatment (Schneider, 2013). Specifically,
toxicities to the cardiovascular system result in decreased stroke volume and cardiac
output and a subsequent reduction in oxygen delivery to body tissues. Similarly,
pulmonary toxicity resulting in fibrosis decreases lung capacity and limits the amount of
oxygen diffusion in the lungs. This also leads to reduced oxygen delivery to the body
and ultimately increased fatigue. Cancer cachexia or other musculoskeletal toxicities
increase protein catabolism, limits cross-bridge formation and muscle contraction, which
contributes to reduced strength and power. This will result in increased feelings of CRF
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in cancer survivors (Bower, 2014; Peterson, Repka, Dallow, Hayward, & Schneider,
2012; Schneider et al., 2003; Schneider, 2013). It has been suggested that up to 100% of
all cancer survivors experience CRF to some degree (Hofman et al., 2007; Koornstra,
Peters, Donofrio, van den Borne, & de Jong, 2014; Weis, 2011; Yeh et al., 2011). Some
reports state that CRF is experienced in 58-94% of breast cancer survivors undergoing
treatment, and 56-95% following treatment (Berger, Gerber, & Mayer, 2012; Cramp &
Byron-Daniel, 2012; Escalante, Manzullo, & Valdres, 2003). The duration a patient may
experience CRF will vary; it may last for months or persist for years following the
completion of treatment. Fatigue can negatively affect physical functioning with up to
91% of cancer survivors receiving chemotherapy reporting difficulty performing
activities of daily living such as cleaning, food preparation, and light lifting (Hofman et
al., 2007). Likewise, CRF may also lead to severe deficits and lead to mental and
emotional distress subsequently reducing overall QOL (Visser & Smets, 1998).
Depression
Depression is one of the most commonly reported emotional symptoms
experienced with cancer and its associated treatments. It can be defined as the
pathological response to loss of normality in one’s personal world as a result of cancer
diagnosis, its treatments, or side effects (Haig, 1992). This disorder affects roughly 2047% of cancer survivors (Pirl & Roth, 1999; Zabora, Brintzenhof-Szoc, Curbow, Hooker,
& Piantadosi, 2001), and occurs two to three times more frequently in the cancer
population than in the apparently healthy (Dauchy et al., 2013). Not only does
depression cause mental suffering, but it can also lead to decreased QOL, increased
sensitivity to pain, and reduced expectation of survival from cancer diagnosis (Gagliese
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et al., 2007; Satin, Linden, & Phillips, 2009; Skarstein, Aass, Fosså, Skovlund, & Dahl,
2000). Although depression negatively affects cancer survivors, it still continues to be
under-diagnosed and is usually left untreated (Dauchy et al., 2013).
Quality of Life
QOL is a multidimensional concept that assesses overall functional, physical,
emotional, psychological, and social well-being in relation to health (Faguy, 2013).
Cancer and cancer treatments have been shown to significantly reduce overall QOL in
cancer survivors, and this reduction in QOL may persist long after treatment has ended
(Jansen, Koch, Brenner, & Arndt, 2010; Lee et al., 2010). The physiological and
psychological side effects from treatment contribute to the overall decrease in QOL.
Cardiovascular and muscular toxicities such as decreased aerobic function and muscle
wasting lead to a reduced ability to complete basic activities of daily living. This can
lead to depression and ultimately decreased QOL. In fact, compared to the apparently
healthy population, QOL is significantly lower in cancer survivors particularly in regards
to mobility, breathing, and vitality (Rauma et al., 2015). Improving QOL is paramount
and should be an integral goal of cancer rehabilitation programs.
Rehabilitation as a Viable Method to Attenuate
Cancer-Related Toxicities
Following the identification of the severe and diverse toxicities experienced by
cancer survivors, clinicians began suggesting that rehabilitation programs may be capable
of attenuating these side effects. Rehabilitation is defined as “the process of restoration
of skills by a person who has had an illness or injury to regain maximum self-sufficiency
and function in a normal or as near normal manner as possible” (Agnes, 2003). The
advent of cancer-specific rehabilitation can be traced to one event, the National Cancer
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Act in 1971 (Alfano et al., 2012). This national research program funded clinical cancer
research centers and other projects in the late 1970’s to investigate the rehabilitative
needs and evaluate interventions established for cancer survivors to improve cancer
diagnosis, treatment, and care delivery. In 1978, Lehmann et al. completed the first and
largest study to assess the rehabilitative needs of a sample of 805 cancer patients from
four different hospitals. The purpose was to determine what type of decrements and to
what extent cancer survivors experience debilitating problems, and to establish the need
for rehabilitative care. Psychological problems represented the greatest percentage
(52%), with generalized weakness, difficulty performing activities of daily living,
ambulation, and communication representing 35%, 30%, 25%, and 7%, respectively.
Following the identification of the most common side effects experienced by the subjects,
the authors sought to determine if appropriate rehabilitative care was received, and if not,
identify the major barriers to patients receiving rehabilitative care. The largest of these
barriers included a general lack of physician referral and familiarity with the concepts of
rehabilitation and financial support. To address this, the authors proposed an
interdisciplinary model with both an educational and a rehabilitative component.
This type of approach to cancer rehabilitation was standard throughout the 70’s,
80’s, and 90’s, with most programs existing in large community or university hospitals
with inpatient care given by a multidisciplinary team of healthcare professionals
consisting of oncologists, physicians, physiatrists, social workers, physical therapists, and
other medical personnel (DeLisa, 2001; Harvey, Jellinek, & Habeck, 1982). These
programs depended upon the facility and medical personnel available, and the level of
coordination between services. The care was diverse, yet highly specific as success was
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measured only by improvements in basic activities of daily living such as ambulation,
food preparation, bathing, etc. (Harvey et al., 1982; Marciniak, Sliwa, Spill, Heinemann,
& Semik, 1996; O'toole & Golden, 1991; Yoshioka, 1994). This model of cancerspecific rehabilitation is no longer prevalent and has lost relevance, which raises the
question, what has changed?
The largest contributing factors to the changes in patient care revolve around
improved prognosis and enhanced survivability. Improvements in detection, diagnosis,
and advancements in treatment have led to vastly different side effects and patient needs.
For example, the radical mastectomy and reconstructive flap procedures were common in
the 80’s and early 90’s. Now breast conserving surgeries are the standard of care, with
reductions in axillary dissection to preserve lymph node function (Alfano et al., 2012).
This has led to a lessened need for specialized and advanced hospital-based rehabilitation
and ultimately a diminished use of the multi-disciplinary approach to patient care.
There is now a disconnect and misunderstanding between what clinicians and
healthcare providers refer to as “cancer rehabilitation.” One thought is that because
cancer survivors still suffer from a myriad of complex disabilities, a single or
unidimensional approach cannot treat the varying limitations (Alfano et al., 2012; Silver
et al., 2015). Whereas, proponents of the unidimensional approach suggest that a single
method can be the cornerstone of care if the effects are profound and can affect the
majority of cancer survivors. The most promising single method of rehabilitation is
structured exercise. The role of exercise intervention as a complementary therapy has
been well documented and unlike other methods, has the capacity to act across multiple
body systems to attenuate cancer-related toxicities (Lakoski et al., 2013; Schmitz et al.,
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2010; Schneider et al., 2002). Through this belief, the Rocky Mountain Cancer
Rehabilitation Institute (RMCRI) was developed by Dr. Carole Schneider in 1996 to
advance the quality of life of cancer patients during and following treatment through
prescriptive exercise rehabilitation (Schneider et al., 2002). The name RMCRI has since
been changed to “University of Northern Colorado Cancer Rehabilitation Institute” or
“UNCCRI” and will hereafter be referred to as such.
Benefits of Exercise on Cancer and
Treatment-Related Side Effects
Exercise has been established as a successful method for primary and secondary
disease prevention in multiple clinical settings (Warburton et al., 2006) and is an essential
mode of rehabilitation for the improvement of both physiological and psychological side
effects in cancer survivors. In 2010 an American College of Sports Medicine (ACSM)
roundtable of experts reported that the psychological and physiological challenges faced
by cancer survivors can be prevented, attenuated, treated, or rehabilitated through
exercise and that physical inactivity should be avoided following diagnosis (Schmitz et
al., 2010). Cancer survivors who exercise on a regular basis during or after treatments
experience significant increases in cardiorespiratory fitness, psychological well-being,
and QOL compared to those who are inactive (Brown, Huedo-Medina, et al., 2012;
Dimeo et al., 1997; Murnane, Geary, & Milne, 2012).
The cardiorespiratory system may see some of the most significant improvements
due to exercise. Aerobic exercise can protect the heart against damage caused by
oxidative stress, which may offset some of the cardiovascular toxicities caused by
treatments. Exercise can result in improved cardiac output, stroke volume, and increased
arteriovenous oxygen difference and unloading of oxygen, which may lead to an increase
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in functional capacity (Kim, Kang, Smith, & Landers, 2006; Schneider et al., 2007b). In
fact, a single bout of acute endurance training twenty-four hours before receiving
chemotherapy preserves left ventricular systolic pressure and attenuates the
chemotherapy-induced decline in left ventricular developed pressure (Wonders, Hydock,
Schneider, & Hayward, 2008). Additionally, the maximum volume of oxygen consumed
(VO2max), which is the gold standard of the measurement of aerobic capacity, has been
shown to improve between 2-40% after an aerobic exercise program in cancer survivors
(Garner & Erck, 2008; Jones et al., 2011; Kim et al., 2006; Klika, Callahan, & Drum,
2009; Marulli et al., 2010; McNeely et al., 2010; Schneider et al., 2007b).
Exercise improves the pulmonary system by strengthening the respiratory and
intercostal muscles and by improving cellular respiration (Zolaktaf, Ghasemi, & Sadeghi,
2013). Increases in pulmonary function are evidenced by improvements in percent of
forced expiratory volume, forced vital capacity, and overall lung function during and
following treatment (Marulli et al., 2010; Schneider et al., 2007b). Additionally,
pulmonary rehabilitation with a mixed low-intensity cardio and strength training
intervention has been demonstrated to reduce expiratory flow limitations and
hyperinflation of the lungs at rest (Yoshimi et al., 2012).
Muscle wasting in cancer survivors has many contributing factors, with increased
protein degradation and decreased protein synthesis being primary causes. Resistance
training directly attenuates cachexia by increasing protein synthesis via the mTOR
pathway, which promotes levels of insulin-like growth factor-1 and mechanical growth
factors (Miyazaki & Esser, 2009; Zanchi & Lancha Jr, 2008). Clinically, strength
training has been shown to significantly increase muscular strength, endurance, and
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power (Kraemer & Ratamess, 2004). After a six-month exercise intervention that
consisted of aerobic, resistance, and flexibility training, cancer survivors improved upperbody and lower-body endurance by 47% and 67%, respectively (Schneider et al., 2007a).
In similar studies, cancer patients have increased upper-body and lower-body strength by
41% and 96%, respectively (Galvão, Taaffe, Spry, & Newton, 2007), and a combined
regimen of aerobic and resistance training significantly improved leg press strength, sitto-stand test results, and overall QOL (Herrero et al., 2006). These improvements in
protein synthesis, muscle cell mass, muscular strength, and muscular endurance increases
the ability to perform activities of daily living which is directly related to improvements
in QOL for cancer survivors, as (Zinna & Yarasheski, 2003).
In addition to increasing cardiovascular endurance, pulmonary function, and
muscular strength, immune function may also increase due to exercise. The immune
system consists of many complex cells, such as natural killer cells and cytotoxic T
lymphocytes, to combat diseases (Nieman et al., 1990). These cells have been known to
increase by as much as 150-300% after exercise (Nieman, 1994). Clinically, a 6-month
exercise intervention in breast cancer survivors found that physical activity increased
lymphocyte activation of T helper cells, concluding exercise may improve immune
function in cancer survivors by increased lymphocyte activation (Hutnick et al., 2005).
Exercise will not only improve physiological variables, but will also improve
psychological variables such as fatigue, depression, and QOL. Fatigue is the most
common side effect experienced by cancer survivors, with approximately 70-100% of the
population reporting some level of fatigue (Cramp & Byron-Daniel, 2012). Exercise
interventions have resulted in a 32 to 39% decrease in fatigue scores (Schneider, 2013),
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and cancer survivors who are physically active have significantly reduced levels of
fatigue when compared to sedentary controls (Brown, Huedo-Medina, et al., 2012;
Carayol et al., 2013; Puetz & Herring, 2012). Improvements may also be seen in
depression scores. Survivors who exercise during treatment as well as following
treatment report decreases in depression by 43% and 25%, respectively (Schneider et al.,
2007b). Perhaps most importantly, QOL is shown to increase with exercise. Cancer
survivors who exercise at least three times a week experience significantly higher QOL
values than those who are inactive (Blanchard et al., 2003). Similarly, it has been well
documented that survivors who are undergoing treatment or have completed treatment
experience significant improvements in QOL following an exercise intervention (Buffart
et al., 2014; Cheema & Gaul, 2006; Courneya et al., 2005; De Backer et al., 2007; Mishra
et al., 2015; Murtezani et al., 2014; Ohira, Schmitz, Ahmed, & Yee, 2006; Zeng, Huang,
Cheng, Zhou, & So, 2014).
Exercise and physical activity yield significant positive effects and attenuate
many toxicities affecting the physiological and psychological function of cancer
survivors. Specifically, exercise can benefit the cardiovascular, pulmonary,
musculoskeletal, and immune systems while concomitantly improving psychological
variables such as fatigue, depression, and quality of life. With this knowledge, it
becomes increasingly clear that exercise is a viable mode of cancer rehabilitation.
In Versus Out of Treatment
During treatment cancer patients experience different and more severe side effects
than they do following treatment. For this reason, the effectiveness of exercise
interventions are thought to differ between patients with different treatment statuses.
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Likewise, the safety of exercise has been questioned for those in treatment (Watkins,
1950). For cancer survivors in treatment, the longevity of side effects will vary from
person to person. Most side effects typically end once cancer treatments conclude, as
healthy cells recover over time (American Cancer Society, 2015). Some side effects,
such as cardiovascular toxicity, may last months or even years following the completion
of treatment (Yeh et al., 2004). Additionally, some studies have observed fatigue to be
prevalent in patients up to eight years following treatment (Wu & McSweeney, 2007).
Although cancer survivors who have completed cancer treatments may still experience
some lingering side effects, those who are still undergoing treatments experience the
worst degree of physiological and psychological toxicities. There are very few studies
that compare side effects experienced in patients receiving treatment against side effects
experienced once treatment is completed. However, one study documented these effects.
It was observed that those who were still completing treatment experienced more severe
fatigue, memory loss, nausea, sleep problems, concentration difficulties, weight loss
problems, and shortness of breath than those who were post treatment (Sprod et al.,
2011).
Although the severity of side effects may differ depending on treatment status,
exercise still remains a safe and viable option of rehabilitation both during and following
treatment. Exercise has been shown to be beneficial for patients who are still undergoing
chemotherapy or radiation. Breast cancer survivors who exercise show significant
increases in functional ability, decreased fatigue, and decreased weight gain during
cancer treatments (Schwartz, 1999; Schwartz, Mori, Gao, Nail, & King, 2001). When
comparing patients who exercised during treatments to those who were sedentary, those
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that exercised maintained pre-chemotherapy VO2max levels, while those that were
sedentary experienced a decline in VO2max (Al-Majid, Wilson, Rakovski, & Coburn,
2015). Correspondingly, survivors who exercised during treatment regimens reported
significantly decreased memory problems, concentration difficulties, weight loss, and
shortness of breath compared to those who were not physically active (Sprod et al.,
2011). Physiologically, systolic blood pressure, diastolic blood pressure, hand grip
strength, upper and lower body strength, and time on treadmill have been observed to
significantly improve even during treatment as a result of an exercise intervention.
Likewise, improvements in psychological values such as total fatigue improve with
exercise (Schneider et al., 2007b). Survivors who have completed cancer treatments
experience similar results. Systolic blood pressure, diastolic blood pressure, resting heart
rate, hand grip strength, overall muscular strength, flexibility, depression, QOL, and total
fatigue have been observed to significantly improve following exercise (Schneider et al.,
2007b; Sprod et al., 2011).
Generation of Cancer-Specific Exercise Guidelines
Exercise and physical activity has been established as a crucial part for a cancer
survivor’s recovery (Schmitz et al., 2010). However, standardized exercise guidelines for
cancer survivors do not exist. Current ACSM guidelines for the apparently healthy adult
population recommend at least 150 minutes of moderate intensity cardiorespiratory
exercise per week. These recommendations can be met by completing 30-60 minutes of
moderate intensity exercise five days per week, or 20-60 minutes of vigorous intensity
exercise three days per week. Additionally, adults should perform resistance training for
each major muscle group two to-three days per week, with the reps and sets varying
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depending on each individual’s goals (ACSM, 2013). The most recent ACSM cancer
exercise roundtable concluded that although physical activity should be incorporated,
exercise guidelines were variable and were dependent on the type of cancer. It was
suggested that patients and clinicians refer to the United States Department of Health and
Human Services (US DHHS) Physical Activity Guidelines (Schmitz et al., 2010).
The US DHHS Physical Activity Guidelines and the American Cancer Society
recommends 150 minutes of aerobic exercise each week at a moderate intensity, or 75
minutes per week of vigorous-intensity aerobic activity (Rock et al., 2012; Tucker, Welk,
& Beyler, 2011). Similar to ACSM’s recommendations, they also suggest performing
resistance training at a moderate or high intensity that involves all major muscle groups at
least two times a week (Tucker et al., 2011). While it is generally agreed upon that
maintaining and improving muscular strength and cardiovascular endurance is important
during and following treatment in cancer survivors, most recommendations regarding
exercise refer to age appropriate apparently healthy recommendations, with slight
modifications. For example, cardiovascular recommendations for both breast and
prostate cancer survivors informs the clinician to be aware of an increased potential risk
for fractures, and when prescribing resistance training for prostate cancer survivors,
pelvic floor exercises should be used (Schmitz et al., 2010). However, researchers have
suggested that recommendations for the apparently healthy may not be applicable for
cancer survivors, as they are too intense (Kuehl et al., 2015; Scharhag-Rosenberger et al.,
2015). Overall these recommendations are very broad and will differ from patient to
patient, which makes the establishment of cancer-specific exercise guidelines difficult.
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Cancer-Specific Exercise Interventions and
Cancer Rehabilitation Programs
The number of cancer survivors continues to increase every year due to
advancements in diagnosis and treatment. Exercise training is a profound therapy that
has the capacity to positively affect multiple systems and reduce most debilitating side
effects. Organizations such as ACSM, the American Cancer Society, and the World
Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) have
established some forms of exercise guidelines for cancer survivors that can give guidance
without the support of a dedicated cancer rehabilitation program. However, rehabilitation
options for cancer survivors are scarce. Surveys have addressed the level of gratification
of current rehabilitative services and issues that have been unmet. The most wanted
services that were reported as universally unavailable consisted of physical training,
physical therapy, psychological counseling, and occupational therapy. As many as 63%
of cancer survivors reported a need for at least one of these services, while 40% stated
that none of their rehabilitation needs were being met (Thorsen et al., 2011).
Additionally, 75-85% of cancer survivors indicated an interested in physical activity and
exercise programs and guidelines (Jones & Courneya, 2002; Stevinson et al., 2009).
Following the creation of UNCCRI, other cancer rehabilitation programs are
beginning to emerge in businesses and hospital settings, such as the Young Men Christian
Association’s gyms and in cardiac rehabilitation clinics (Dittus et al., 2015). Of note,
these new programs are not specifically and judiciously structured and lack clear
methodology. Most do not provide the appropriate assessment, prescription, and
interventions needed to directly target the toxicities caused by cancer treatments
(Schneider et al., 2002). Finally, there is still no clear method of exercise prescription for
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the cancer population that takes treatment status and placement on the cancer continuum
into account and supports the findings with scientifically based evidence
Cancer-Specific Exercise Prescriptions
Exercise prescription refers to specific exercise guidance prescribed for an
individual that is designed for a specific purpose or purposes. In cancer rehabilitation,
the exercise prescription is the design of a rehabilitative exercise program for the cancer
survivor and may or may not have physician approval. Exercise prescriptions should
have at least these three primary objectives (ACSM, 2013): 1) to increase physical
fitness, 2) to improve health by reducing the risk factors for chronic disease, and 3) to
ensure safety during exercise (Brown, Hash, & Lyons, 2001). These are especially
important to a cancer survivor, as many have decreased fitness levels (Tisdale, 2009; Yeh
et al., 2004) and more risk factors due to cancer and the concurrent treatments (Schneider
et al., 2002; Schneider et al., 2007b). Additionally, there is an increased susceptibility for
falls and/or injury in the cancer population (Stone, Lawlor, Nolan, & Kenny, 2011;
Winters-Stone et al., 2011). For these reasons, inaccurate prescriptions can lead to
dangerous situations and can compromise a patient’s health (Brown et al., 2001)
Proper exercise prescription in cancer survivors includes two distinct components.
The first essential prerequisite is detailed medical and cancer screening and
comprehensive physiologic and psychologic assessment (Sasso et al., 2015; Schneider et
al., 2002). The exercise prescription should be individualized according to a cancer
survivor’s treatment status, medical comorbidities, aerobic fitness, muscular strength and
endurance fitness, and negative effects of treatments experienced at any given time
(Schmitz et al., 2010).
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Second, the exercise prescription should apply the principles of exercise training:
individuality, specificity, progressive overload, rest/recovery, diminishing returns, and
reversibility (Campbell et al., 2012; Sasso et al., 2015). The principle of individuality,
which can be thought of as the customized application of training mode and intensity
towards the physiological status of the patient, is the most integral, as individual response
to exercise, rate of development, and program structure will differ for every patient
(Brown et al., 2001). The principle of specificity states that the prescribed exercise must
be specific and target the designated system(s) or pathway(s) to achieve the desired result
(e.g., aerobic exercise to affect the cardiovascular system). This is particularly relevant
in cancer rehabilitation, as the goal is to alleviate treatment toxicities affecting specific
systems. Progressive overload alters the frequency, intensity, time and type (FITT) of
exercise so that the body and targeted organ systems are overloaded beyond equilibrium.
This overload results in biological stress and overcompensation, wherein the body can
withstand greater future stress. Repeated bouts of overload lead to further enhancements
of the system. The principle of progressive overload is of the utmost importance in the
creation of appropriate exercise prescriptions. If the prescription does not result in
overload, physiological adaptations will not occur, however, if the exercise dose results
in chronic overload without rest, patients may experience increased fatigue, injury, and
myelosuppression thereby increasing the susceptibility to illness. The principles of
diminishing returns and reversibility have yet to be adhered to consistently in the cancer
population. Diminishing returns refers to the thought that continued physiological
improvements will begin to lessen as training continues and will cease once a patient’s
“genetic ceiling” has been reached. Reversibility refers to the concept that the cessation
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of exercise will result in a reduction and eventual loss of the physiological adaptations
achieved by exercise.
Despite knowledge of the importance of medical screening, assessment, and
adherence to the principles of exercise training, implementation of current exercise
guidelines into clinical practice and the successful creation of exercise prescriptions for
cancer patients is challenging. Similarly, ACSM’s recommendations often are unusable
in the creation of exercise prescriptions due to the general lack of data and relatively
broad guidance (Wolin, Schwartz, Matthews, Courneya, & Schmitz, 2012).
Due to unclear or vague guidelines regarding exercise for cancer survivors, many
clinicians are left to use their past experience to progress a patient through their exercise
intervention, sometimes without the creation of an appropriate exercise prescription. Of
great concern, it appears that clinicians and programs are neglecting the principles of
exercise and thus limiting the positive outcomes of an exercise program. Maintaining
these principles ensures the most appropriate type and dosage of exercise to obtain
desired results. In studies involving exercise interventions for cancer survivors, many fail
to adhere to the principles of exercise training. In a recent analysis by Campbell et al.,
(2012), only 41% and 31% of programs adhered to the principles of progression and
overload, respectively, and only 3% to the principles of diminishing returns and
reversibility. Additionally, many of these studies failed to report the components of the
exercise prescription being used. Thirty-four percent of the studies evaluated failed to
report all components of the prescription and as a result these studies have yielded
unreproducible results (Campbell et al., 2012). Although there is a plethora of research
investigating exercise and cancer rehabilitation, the lack of appropriate medical screening
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and assessment compounded with the failure of programs and interventions to adhere to
the principles of exercise training has resulted in the absence of a clear and standardized
method of cancer-specific exercise prescription.
The University of Northern Colorado Cancer Rehabilitation Institute’s program
has been the only rehabilitation model to date, that has consistently and from its inception
complied with the first essential component of exercise prescription. Entry into the
program begins with physician referral, cancer and medical screening, and assessment of
initial physiologic and psychologic values. The exercise prescription is then created with
a focus on the patient’s treatment status, medical information, and assessment results. In
UNCCRI’s earliest model, patients were divided based on if they were currently in or
following treatment, and changes to the exercise prescription were determined by the
changes in treatment status. Only the principle of progression is mentioned in this model,
however the application is unclear, as the rate of progression during the exercise
intervention is based on the aforementioned criteria and is only referred to as “slow”.
Recommended starting intensities were suggested based on health status. Those who
were sedentary or in poor health began exercise at an intensity of 30%-40% heart rate
reserve (HRR), while those who were active or in moderate health began at 50%-60%
HRR (Schneider et al., 2003; Schneider et al., 2002). Regardless of the lack of
recognition and adherence to the principles of exercise training, this program has yielded
the largest dataset and greatest amount of literature demonstrating the model’s
effectiveness at attenuating treatment-related side effects in cancer survivors (Hydock et
al., 2012; Schneider et al., 2003; Schneider et al., 2002; Schneider et al., 2007a, 2007b;
Schneider, 2013; Sprod et al., 2011; Sprod, Hsieh, Hayward, & Schneider, 2010;
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Wonders et al., 2008). The violation of the principles of exercise do not appear to affect
this model’s effectiveness during the first 3-to-6 months of the exercise intervention.
However, long-term analysis of this program’s results have demonstrated a decline and
plateau in improvements observed in measures of cardiovascular endurance and muscular
endurance. In fact, after an initial 13% and 32% improvement in cardiovascular and
muscular endurance, respectively, following 3-or-6 months of the program, both
variables proceeded to plateau or decrease by reassessment at 21 months. This final
reassessment represented the end of the rehabilitation intervention, however the majority
of patients still fell into the poor or well below average classifications of cardiovascular
endurance. It was suggested that the exercise prescription and intervention failed to
properly utilize the principle of progressive overload to ensure continual progression
throughout the intervention (Brown, Lalonde, et al., 2012). To address this issue,
UNCCRI redesigned the process of exercise prescription to ensure all components are
met and the principles of exercise training are prominent and adhered to throughout.
Creation of the Phase Training Model
of Cancer Rehabilitation
To date, there exists no standardized model of exercise-based cancer
rehabilitation and no program has effectively maintained all essential components of
exercise prescription in the cancer population (Campbell et al., 2012; Sasso et al., 2015;
Schmitz et al., 2010). Specifically regarding the exercise prescription there are no
consistent or set guidelines on what intensity a cancer survivor should be exercising at in
relation to placement on the cancer continuum and in regards to diagnosis, treatment
status, or assessment results. There are however, suggestions on exercise training based
off intensity classifications. Low exercise intensities have ranged from 25-50% HRR,
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moderate intensities from 35-66% HRR, vigorous intensities from 58-85% HRR, and
near-maximal intensities > 90% HRR (Heinrich et al., 2015; Kuehl et al., 2015;
Scharhag-Rosenberger et al., 2015; Schneider et al., 2003). However, there are no
guidelines on when cancer survivors should perform each intensity classification or what
data would guide the clinician to alter the prescription. The proposed Phase Training
Model establishes set exercise guidelines and intensities in relation to placement on the
cancer continuum, status of treatment, medical information, and data collected from an
initial assessment. This model is divided into distinct sections which represent patients
who differ based on the aforementioned criteria.
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CHAPTER III

METHODOLOGY
Subjects
Data obtained from patients participating in the UNCCRI cancer rehabilitation
program between the years 2012-2016, and following implementation of the Phase
Training Model were used. Participants were male and female cancer survivors over 18
years of age who were undergoing or had completed surgical intervention, chemotherapy,
radiation therapy, immunotherapy, hormonal therapy, stem cell, gene, or bone marrow
transplantation, and/or other types of unconventional treatment. Safety of the participants
was ensured throughout all data collection, exercise testing, and exercise training. All
cancer survivors were cleared to participate in an exercise program through a referral
completed by each individual’s oncologist or physician, and a detailed medical and
cancer history for each participant was faxed with each referral. Prior to any data
collection, all participants were informed that they were volunteers and can terminate
their involvement in the program at any time. An informed consent (see Appendix A)
was provided. Each subject, following a thorough explanation of the program, signed the
consent form and agreed to participation. All protocols used for the study were approved
by the University of Northern Colorado’s (UNC) Institutional Review Board (see
Appendix B). All data collected and all exercise testing and training took place at
UNCCRI on the University of Northern Colorado’s campus in Greeley, Colorado.
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Experimental Design
The purpose of this study was to evaluate the effects of the UNCCRI Phase
Training Model on cardiorespiratory endurance, muscular strength, and cancer-related
fatigue in cancer survivors during the transition from each Phase and in those who have
completed the entire UNCCRI Phase Training Model.
All participants’ data were obtained from initial assessments and subsequent
reassessments while participating in the Phase Training Model. The Phase Training
Model of cancer rehabilitation utilizes a four Phase approach with assessments of
physiological and psychological variables conducted at each assessment. Participants
performed initial assessments upon entering the program and completed reassessments
every 12 weeks until four reassessments had been completed. Each reassessment marked
the completion of that specific Phase and subsequent entry into the next. The order of
initial assessments and reassessments is graphically represented in Figure 1.

Figure 1. Initial assessments and the corresponding reassessments
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Entry into the program depended on the patients’ treatment statuses (allowing entry as
Phase 1 or Phase 2), and thus altered the length of program completion. Phases 1 through
3 were considered “true cancer rehabilitation”, and the program was marked as
completed once the patient had entered Phase 4. However, continued reassessment took
place as patients continue the Phase Training Model in Phase 4 and was referred to as
personal training. Patients who entered the program as Phase 1 completed the program in
36 weeks, while those who entered as Phase 2 completed the program in 24 weeks. The
points, A, B, C, and D in Figure 1 represent specific time points of data collection in the
Phase Training Model. Each point represents the entry and subsequent transition from
one Phase to the next.
A. Phase 1 to Phase 2: Patients entering the program as Phase 1. This marks the
entry into and completion of Phase 1. Subsequently this marks the entry into
Phase 2.
Phase 2 to Phase 3: Patients entering the program as Phase 2. This marks the
entry into and completion of Phase 2. Subsequently this marks the entry into
Phase 3.
B. Phase 2 to Phase 3: Patients have completed the first reassessment marking
completion of Phase 2 and the subsequent transition into Phase 3.
Phase 3 to Phase 4: Patients have completed the first reassessment marking
completion of Phase 3 and the subsequent transition into Phase 4. The program has
been completed.
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C. Phase 3 to Phase 4: Patients have completed the second reassessment marking
completion of Phase 3 and the subsequent transition in Phase 4. The program has
been completed.
D. Phase 4 to Phase 4: Patients have completed the second reassessment and are still
in Phase 4.
All procedures, assessments, and measurements were conducted by trained Cancer
Exercise Specialists (CES) and were overseen by the UNCCRI Clinical Coordinator.
Preliminary Paperwork and Patient Screening
Following participant referral and signing of the informed consent, each
participant was asked to complete questionnaires evaluating psychological functioning,
lifestyle, behavior, and medical information. The questionnaires included: a
Lifestyle/Activity Evaluation (Appendix C), a Medical History (Appendix D), the
Revised Piper Fatigue Scale (Appendix E), the Beck Depression Inventory (Appendix F),
and the Ferrans and Powers Quality of Life Index Version III (Appendix G). All
questionnaires were completed prior to assessment.
Lifestyle/ Activity Evaluation: This questionnaire evaluated the participants’
personal lifestyle choices regarding smoking, drinking, sleep, physical activity, and diet.
Medical History: Participants’ medical information was obtained via this self-reported
worksheet detailing present medical history, family medical history, medications,
allergies, and cancer diagnosis. If needed, further medical information was requested
from the participants’ oncologist or primary care physician.
The Revised Piper Fatigue Scale: Fatigue was measured via the Piper Fatigue
Inventory, which evaluates total cancer-related fatigue, as well as subscales of fatigue
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such as affective, behavior, cognitive, mood, and sensory. These individual subscales
comprise 22 points with the average score representing total fatigue. The scale ranges
from 0 to 10. A score of 0 indicates that the participant shows no sign of fatigue, a score
from 1 to 3 indicates mild fatigue, 4 to 6 indicates moderate fatigue, and a score of ≥7
indicates severe fatigue (Piper et al, 1998).
Beck Depression Inventory: This inventory is a valid and reliable (Vodermaier,
Linden, & Siu, 2009) 21 question index that assessed symptoms such as, but not limited
to hopelessness, feelings of being punished, weight loss, and guilt. Higher scores
indicate greater depression with 0 indicating no depression and >40 indicating extreme
depression.
Ferrans and Powers Quality of Life Index Version III: This 66-question
questionnaire is designed to evaluate social, psychological, family, and health satisfaction
as well as total QOL. Higher scores indicate greater satisfaction in QOL (Ferrans &
Powers, 1985).
Prior to the initial assessment and each subsequent reassessment, a detailed
medical and cancer screening was recorded on the Client Summary form (see Appendix
H). The Client Summary listed all pertinent cancer information, treatments, surgeries,
medications, current health status, and personal patient goals.
Phase Training Model: Assessment Protocols
Initial assessments occurred prior to the creation of the exercise prescription and
exercise intervention. Reassessments occurred after each 12-week exercise intervention
and every 12 weeks until four consecutive reassessments had been completed. Each
assessment included the measurement of vitals, body composition, functional
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assessments, balance, pulmonary function, cardiovascular endurance, muscular strength
and endurance, and flexibility and range of motion (ROM). The results from the
assessment protocols were recorded on the Data Collection Sheet for the corresponding
Phase (see Appendices I-K).
Vital Measurements
Prior to any exercise testing and throughout all physical activity, participants’
heart rate, oxygen saturation (SPO2), and blood pressure were assessed via a heart rate
monitor with chest strap (Polar, Inc. Lake Success, NY), pulse oximeter, and
sphygmomanometer and stethoscope, respectively.
Body Composition
Body fat was first assessed via the three-site skinfold (SKF) test (Jackson &
Pollock, 1978; Jackson, Pollock, & Ward, 1979) by using skinfold calipers. The threesite SKF locations for men were: the chest, abdomen, and thigh. The three-site SKF
location for women were: the tricep, supraliliac, and thigh. Two measurements, in a
rotational order, were taken; a third was taken at any site that differed by more than 2
millimeters. Waist-to-hip ratios were measured. A tape measure was utilized to measure
the narrowest and the widest part of the lower thoracic region to obtain a waist and hip
measurement, respectively. Body fat was also taken using a bioelectrical impedance
machine (InBody 770, Cerritos, CA.). The InBody 770 machine involved the subject
standing on a scale platform for no longer than one minute while holding a sensor in each
hand.
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Functional Assessments
The anatomical plumb line and the National Academy of Sports Medicine
(NASM) overhead squat assessment were used to assess any functional deviations. For
the anatomical plumb line test, the participant was instructed to stand as straight as
possible against a door frame or any straight vertical line against a wall. The participant
was then viewed anteriorly, posteriorly, and from the sagittal plane. From each view, any
irregularities in posture or stance, such as shoulder elevation or depression were
documented.
For the NASM squat test, the participant was asked to squat between one to five
seconds while holding his or her arms above the head. This was repeated two to three
times, as the participant was viewed from the anterior, sagittal, and posterior planes. Any
deficiencies from a normal squat, such as a rounded back, were noted.
Balance
A Bertec BalanceCheck Screener™ (Bertec) (Bertec Corporation, Columbus,
OH.) was used to assess balance. Height was obtained before the balance assessment
using an InBody Stadiometer (InBody, Cerritos, CA.). The Bertec used a series of tests
to assess the subject’s ability to maintain balance while standing on a stable surface and
an unstable surface. The subject stood as still as possible with feet placed so that the
medial malleolus of each ankle lined up with a designated line on the Bertec force plate.
The first test required the subject to stand as still as possible with his or her eyes open;
the second test required the eyes to be closed. Two similar tests were administered with
the participant standing on an unstable, foam surface. A limits of stability test was also
performed, in which the subject moved dynamically, as far as possible, towards the front,

40

back, left, and right with movement occurring from the subtalar joint of the ankle. The
subject returned to the center position before completing each direction. Scores were
recorded at the conclusion of all the tests.
Pulmonary Assessment
Participants’ pulmonary function was evaluated using a spirometer (Spirolab III
MIR, Rome, Italy). Before the test was conducted, participants were given nose plugs to
wear and were instructed to place a disposable mouthpiece in the spirometer. The
participant was instructed to form a tight seal on the mouthpiece and blow into the
spirometer as forcefully and for as long as possible. Prior to the test, the participant was
asked to take a couple of deep breaths in and out before giving a final effort. This test
was performed twice, and if there was variance greater than 5% between the two tests, a
third test was administered. The highest values of force vital capacity (FVC) and forced
expiratory volume (FEV1) were recorded.
Cardiovascular Endurance Assessment
Cardiovascular endurance was evaluated using the cancer-specific UNCCRI
Treadmill Protocol which yields VO2peak values. This protocol was found to be the most
accurate and appropriate for the cancer population (Shackelford, 2015). The goal of this
test was for the participant to reach self-perceived maximal exertion or fatigue. The
highest measurement of oxygen consumption was calculated. This protocol consists of
one minute stages, which increase speed and/or incline at the conclusion of every stage.
During the test, heart rate (HR) and oxygen saturation (SPO2) was collected at the end of
every minute. Blood pressure (BP) was recorded at the end of every three minutes, as
well as the participant’s rating of perceived exertion (RPE) on the modified Borg Scale.
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This RPE scale consists of numbers 0-10 which correlates to the perceived intensity of
the test. A RPE of 0 correlates with the intensity of a stroll in the park, and a RPE of 10
signifies the patient has reached his or her maximal effort and cannot continue. The use
of handrails was discouraged, but was allowed if deemed necessary. Handrail usage must
stay consistent throughout the test. Termination criteria of the test were: participant
reached volitional fatigue or asked to stop for any reason, failure to increase systolic BP
or HR with increased intensity, fluctuation of more than 10 mmHg from resting measures
in diastolic BP, or oxygen saturation drops below 80 on the pulse oximeter. Once the
testing ended, each subject completed a cool-down period, where all of the
aforementioned variables were measured in the same manner as during the test. Final
treadmill time, BP, HR, and RPE was recorded. Peak volume of oxygen consumption
was estimated using ACSM’s walking and running equations, which have been found to
be valid in determining VO2peak (Shackelford, 2015).
Muscular Strength Assessment
Muscular strength was assessed via the estimated one-repetition maximum
protocol (EST 1-RM) using the Brzycki equation. This test used Cybex Eagle resistance
machines (Cybex Inc., Medway, MA.), and specifically utilized the following machines:
chest press, lat pulldown, seated row, shoulder press, leg press, leg curl, and leg
extension. The goal of this test was to have the participant lift as much weight as
possible between one and ten repetitions. RPE values were asked at the end of every set.
The test was performed in six steps. (1) Before the participant began the test, the CES
demonstrated how to perform each machine correctly with proper form, and adjusted the
machine to ensure a proper fit for each participant. (2) The participant was then asked to
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perform a warm-up set, which consisted of five repetitions at a low intensity. (3) After
the warm-up set, the weight was increased accordingly to elicit muscular failure or
fatigue between 1 and 10 repetitions. (4) The participant then attempted to lift the weight
deemed appropriate to elicit failure between 1 to 10 repetitions. (5) If the weight
appeared to be too light to elicit failure between 1 to 10 repetitions, the set was stopped
immediately and the weight increased. If the weight was too heavy for even one full
repetition, the weight was reduced accordingly. (6) Finally, after a 2 to 3 minute rest,
steps 4 and 5 may have been repeated up to two times per machine to elicit a weight that
resulted in muscular fatigue between 1 and 10 reps. The EST 1-RM values, as kilograms
(kgs) lifted, were recorded for each machine. The leg and chest press values were then
divided by the patient’s body weight, both in kgs, to yield a strength-to-weight ratio for
each machine.
Handgrip strength was measured using a handgrip dynamometer (Takei Scientific
Instruments Co., LTD., Niigata City, Japan). The handgrip size was adjusted accordingly
for every individual. The participant was asked to hold the dynamometer by his or her
side with the dial facing away from the body. They were then instructed to squeeze the
dynamometer as hard as possible until told to stop (about two to five seconds) without
moving or swaying the arm. This was done three times for each hand, alternating hands
between each attempt. The highest values for each hand were recorded.
Muscular Endurance Assessment
Muscular endurance of the core and lower body were measured via the plank test
and the chair squat test, respectively. The plank test required the patient to begin in a
prone position on his or her hands and knees. They were then instructed to transition
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from the hands to the forearms, and to extend the legs so they were on their toes. They
were instructed to hold their hips in a neutral spine for as long as possible, or up to a
maximum of 60 seconds. The final time was recorded in seconds.
To administer the chair squat test, a chair was positioned against a wall directly
behind the patient. The patient was instructed to cross his or her arms across the chest
and to squat down into the chair so that the buttocks briefly touched the seat of the chair.
As soon as they touched the chair they were instructed to return to the standing position.
The participant continued to do this until physical exhaustion was achieved, the cadence
of movement slowed, or the maximum time of 60 seconds was reached.
Flexibility and Range of Motion Assessment
The modified sit-and-reach (SR) test, back scratch test, and reaching tests were
used to assess flexibility and range of motion. For the modified SR test, the participant
was instructed to sit on the floor with his or her shoulders, head, and hips against a wall.
The legs were extended in front of them, with their feet flat against a 12-inch SR box.
The participant then extended his or her arms out, with one on top of the other. The end
of the arm of the SR box was positioned so it was at the end of the participant’s
fingertips. The participant was instructed to bend forward at the hips and slide the
fingertips along the arm of the SR box until no further extension was possible. The value
was recorded in centimeters. This procedure was conducted two additional times, and the
highest value recorded.
The back scratch test required the patient to reach up and behind their back with
the dominant hand, palm facing the back. They were asked to reach the other arm down
and behind the back as far as possible, with the palm facing away from the back. Both
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wrists were kept as straight as possible. The distance between each middle finger was
used as landmarks and the distance in centimeters recorded. If the fingertips touched
without overlapping, the score was recorded as zero centimeters. If they did not touch,
the score was recorded as a negative value in centimeters, and if they overlapped it was
recorded as a positive value in centimeters.
For the reaching tests, the participant was asked to reach as far as possible with
both arms in the anterior plane, and then the sagittal plane. Arms were kept as straight as
possible. The highest score in each plane (anterior: 1 to 4; sagittal: 1 to 8) was recorded.
Phase Training Model: Exercise Prescription
Exercise prescription took place following the assessment and was created using
the Client Overview document (see Appendix L). The Client Overview indicated the
Phase the participant is stratified into, the starting target intensity of both the aerobic and
resistance training components of the program, and the rate of progressive overload
prescribed during the 12 weeks for each subject. The participant screening, which was
recorded on the Client Summary, and the data collected from each assessment protocol,
which was recorded on the Data Collection Sheet, were used together to create the
exercise prescription for each participant. Specifically, the treatment status (during
versus following) and the types of treatment received dictated the Phase the client entered
the program in. If the subject was currently undergoing chemotherapy and/or radiation
therapy, he or she was placed in Phase 1. If treatment had ended at entry into the
program or if the subject underwent surgical intervention and/or other treatments
(hormonal, immune, etc.), he or she was placed in Phase 2. The assessment results and
specifically the classifications achieved by the participant during each assessment were
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utilized to begin the process of selecting the appropriate target intensity of the
intervention. For example, if the subject performed very poorly on the UNCCRI
Treadmill Protocol and yielded a classification of low in cardiovascular function when
compared to other cancer survivors, this indicated a prescription at the lowest end of the
Phase recommendations for HRR was needed. Likewise, if a subject performed well on
the EST 1-RM protocol and achieved a strength-to-weight ratio that indicated an above
average ranking, the resistance training intensities at the higher end of the range
recommended by the Phase were prescribed. The Client Summary further assisted the
prescription of intensity as the principle of individualization and specificity were utilized
in relation to each patient’s specific goals and desired outcomes from the program. If a
participant’s goal consisted of being able to walk or jog a 5-K race at the conclusion of
12 weeks, and if the medical history indicated this would not jeopardize the patient’s
immune function, then a steeper progression of intensity during the aerobic intervention
was prescribed. Similarly, if a participant’s goals included competing in a weight lifting
competition as part of the local Senior Games, a prescription utilizing more assertive
progressive overload was included during resistance training. The Client Overview
ensured that both essential components of exercise prescription were included,
assessment results and adherence to the principles of exercise training.
The Phase Training Model: Exercise Intervention
Each exercise intervention session took place at UNCCRI. Physiological data
were recorded by UNCCRI CES’s. The Phase Training Model assured that the five basic
principles of exercise were being met. The main principles included progressive
overload, individuality, specificity, diminishing returns, and reversibility. The intensity
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of the exercise intervention was dictated by the exercise prescription and was dependent
upon treatment status, assessment results, and ascribed Phase. A graphic representation
of the Phase Training Model is shown in Figure 2. One-on-one training occurred in the
first three Phases, with the option also being available in Phase 4. For all one-on-one
sessions, a whole body exercise intervention was utilized. The frequency of training was
prescribed as three sessions per week for 12 weeks. The duration of each exercise
session was 60 minutes with 20 minutes designated for cardiovascular exercise, 30
minutes for resistance exercise, 10 minutes for flexibility training, and with balance
exercises incorporated throughout the entire session. The following modes were utilized
for the aerobic portion of the exercise session: treadmill, cycle ergometer, NuStep,
Aquaciser (underwater treadmill), outdoor walking or jogging. In regards to resistance
exercise, each session targeted the following muscle groups: chest (pectoralis major and
minor), back (rhomboids and latissimus dorsi), lower body (quadriceps and hamstrings),
and core (trunk stabilizers and pelvic floor), and utilized three sets of 10 repetitions of
each exercise. Other muscle groups may have been included (deltoids, biceps, triceps,
adductors, etc.) within the 30 minutes of strength training. Modes of resistance training
included: Cybex® resistance machines, therabands, dumbbells, medicine balls, body
weight, and resistance tubing. The flexibility portion utilized stretches targeting all
muscle groups that were used during the exercise session. Additional equipment that aids
in the stretching portion included: rope pulleys, range of motion wheels, and ropes. For
the addition of balance, the following equipment was used: ski poles, stability balls, Bosu
balls, Ballast balls, dyna disks, wobble boards, and foam pads. Prior to the start of each
exercise session, resting HR, BP, and SPO2 were measured and current health was
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assessed via discussion with the participant. A heart rate monitor was worn throughout
the entire session by the participant. At the conclusion of every session, HR, BP, and
SPO2 were measured to ensure values were near resting measures and the participant was
safe to leave the facility.

Figure 2. Phase Training Model of Cancer Rehabilitation
Phase 1 was developed for cancer survivors who are still receiving chemotherapy
or radiation treatments. Due to side effects being more prevalent while in treatment as
opposed to out of treatment (Sprod et al., 2011), the goal of this Phase was to maintain or
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slightly increase a cancer survivor’s physiological and psychological values. Phase 1 was
specifically designed to adhere to the principles of individuality and specificity.
Decrements below baseline should not have occurred, as this Phase was designed to
attenuate the toxicities from cancer treatment. The starting intensity was categorized as
low (Kuehl et al., 2015; Schneider et al., 2003) with intensity ranging between 30-45%
HRR and EST 1-RM. This intensity was determined by reviewing over 100 exercise
logbooks from clients that were currently undergoing treatment. The mean training
intensity was well tolerated among patients and varied between 30-45% HRR, which
corresponds with intensities for those in poor health (Schneider et al., 2003). Participants
remained in this Phase for the duration of his or her cancer treatment or for 12 weeks, if
treatment concluded prior to the entry into the next Phase. Of note, usage of any aquatic
exercises was prohibited during this Phase due to skin irritation resulting from treatment.
Phase 2 was designed for cancer survivors who have moved from Phase 1 to
Phase 2, or for any survivor who had undergone cancer treatment that was not
categorized as chemotherapy or radiation therapy. Other forms of treatment included
hormonal altering or blocking therapy, immunotherapy, or stem cell transplants. Side
effects from a survivor undergoing chemotherapy or radiation differ from the side effects
experienced during other forms of treatment which are generally less severe (Collins et
al., 2011). Due to this, the starting intensity of Phase 2 was prescribed as low-tomoderate (Kuehl et al., 2015); and ranged between 40%-60% HRR and EST 1-RM. The
intensity was determined by reviewing over 100 exercise logbooks for those who had just
completed cancer treatments. This intensity range was closely related to intensities
previously reported for the active, cancer patient (Schneider et al., 2002). The goal of
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Phase 2 was to build a foundational base using corrective and functional training with a
focus on developing and stabilizing the core, pelvic floor, shoulder girdle, or any other
joints or muscles affected by surgery and/or hormonal treatments, and the lasting effects
from chemotherapy or radiotherapy. Stabilizer muscles such as the core, pelvic floor, and
shoulder girdle are prominently affected by cancer and its treatments (Collins et al., 2011;
Swenson et al., 2002). Strengthening these components of the body will assist with
activities of daily living and general movement patterns. Phase 2 was designed to
continue adherence to the principles of individuality and specificity, and to begin
incorporating progressive overload based on assessment results and treatment deficits.
Typically, a client remained in this Phase for 12 weeks.
Phase 3 was intended for cancer survivors who have completed Phase 2, and was
the transitional Phase from cancer rehabilitation to apparently healthy exercise. As Phase
3 represented the last Phase considered cancer rehabilitation, a major goal was to educate
participants with the skills necessary to implement and maintain an exercise program on
their own. Participants should have transitioned from Phase 3 with the ability to perform
exercises with self-efficacy and knowledge to avoid injury and create progression. This
goal existed to support the principles of diminishing returns and reversibility. Phase 3
also aimed to improve physiological and psychological values beyond baselines and to
incorporate the principle of progressive overload to the highest extent. Improvements
have occurred in cardiovascular fitness, muscular strength and endurance, pulmonary
function, flexibility, and balance. Psychological improvements should have been visible
via QOL, depression, and fatigue scores. At completion, cancer survivors should have
achieved classification near or at apparently healthy status. This type of training was
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classified as moderate-to-high, as intensities ranged between 60-85% HRR and EST 1RM. This range has been deemed appropriate for vigorous exercise (Kuehl et al., 2015;
Scharhag-Rosenberger et al., 2015) and overload. A cancer survivor remained in this
Phase for 12 weeks.
Phase 4 was designed for cancer survivors who have completed Phase 3, and there
was no time limit for this Phase. Cancer survivors in this Phase had successfully
completed the prior three Phases, and were deemed close or at apparently healthy status.
Phase 4 was not considered cancer rehabilitation as it was meant to assist patients for the
rest of their lives in maintaining physical activity and healthy function. Unlike the other
three Phases, additional alternatives to one-on-one training were available. Patients may
have chosen to participate in group fitness classes or attend an open gym schedule at
UNCCRI. The goal of this Phase was to maintain improvements in both physiological
and psychological values gained during the past Phases or continue progressive overload
based on the patient’s personal goals. The type of training was classified as moderate-tonear-maximal, as the range of intensities was 65-95% HRR and EST 1-RM. This
intensity range was appropriate for cancer survivors who are or close to apparently
healthy status (Kuehl et al., 2015; Scharhag-Rosenberger et al., 2015).
Statistical Analysis
Individual paired-sample t-tests were utilized to examine if significant differences
occurred in cardiovascular endurance, muscular strength, and fatigue during each Phase
transition. The following dependent variables were measured: VO2peak, EST 1-RM of the
leg press, EST 1-RM of the chest press, strength-to-weight ratio for the leg press,
strength-to-weight ratio for the chest press, and fatigue. The following Phase transitions
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(assessment and reassessment) were evaluated: Phase 1 to Phase 2, Phase 2 to Phase 3,
and Phase 3 to Phase 4. Because several paired t-tests were utilized, a Bonferroni
adjustment was used to reduce the chance of committing type I error. Statistical analyses
will be performed using the Statistical Package for the Social Sciences software package
(SPSS, Chicago, IL.). Significance levels were set at p < 0.05.
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CHAPTER IV

RESULTS
The purpose of this study was to evaluate the effects of the Phase Training Model
on cardiorespiratory endurance, muscular strength, and cancer-related fatigue in cancer
survivors during the transition from each Phase and in those who have completed the
entire Phase Training Model.
Participant Characteristics
Table 1 displays the demographic characteristics of the participants. A total of
152 cancer survivors’ data were utilized to assess the Phase Training Model. The study
consisted of 58 males and 94 females, where the mean age was 62 ± 12 years of age and
the mean weight was 80 ± 21 (kgs). Table 2 depicts the total number of assessments and
Phase transitions that occurred among the participants. Of these, 87.7% of the
assessments represented standard Phase transitions from one Phase to the subsequent
Phase, whereas 12.3% were non-standard transitions in which the individual remained in
the same Phase for an additional 12 weeks. Non-standard Phase transitions occurred
from Phase 1 to Phase 1 during continued chemotherapy and/or radiation treatment, from
Phase 2 to Phase 2 when there existed lasting functional and postural deviations that
required additional time to attenuate, and from Phase 3 to Phase 3 due to a participant
that required further education and motivation to learn proper form, exercise creation, and
generate the self-efficacy needed to establish an exercise intervention. Tables 3, 4, and 5
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display the cancer types, treatment demographics, and cancer stages, respectively.
Cancer types included: Breast (36%), liquid (12%), prostate (11%), lung (11%), head and
neck (7%), gynecological (5%), colorectal (4%), and other cancer types (14%). Of the
participants, 13% had surgery only, 9% had chemotherapy only, 3% had radiation only,
26% had surgery and chemotherapy only, 18% had surgery and radiation only, 3% had
chemotherapy and radiation only, 27% had surgery, chemotherapy, and radiation, and 1%
had no treatment. For those who had completed treatment, the average time post
treatment was 10 months. Of the participants, 24%, 26%, 24%, and 14% were diagnosed
as stage 1, 2, 3, or 4, respectively; stage was unknown or was not staged in 12% of the
participants.
Mean attendance of all subjects participating in the program was 80% and average
retention was approximately 58% between each Phase Transition until program
completion. Retention for those who began in and completed Phase 1 was 54%. For
those who entered the program as Phase 2, retention was 65%. Finally, retention for
those who completed Phase 3 and completed the program into Phase 4 was 54%. Of the
152 program participants, 33 completed the entire Phase program from entry through
Phase 4.
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Table 1
Participant Characteristics
Participant Characteristics

N = 152

Age (years)

62 ± 12

Male, n (%)

58 (38)

Female, n (%)

94 (62)

Height (centimeters)

168 ± 10

Weight (kilograms)

80 ± 21

Table 2
Assessments and Phase Transitions
Phase Transitions

N (%)

Total Assessments

292

Phase 1 to Phase 2

43 (14.7)

Phase 2 to Phase 3

126 (43.2)

Phase 3 to Phase 4

68 (23.3)

Phase 4 to Phase 4

19 (6.5)

Phase 1 to Phase 1*

16 (5.5)

Phase 2 to Phase 2*

13 (4.5)

Phase 3 to Phase 3*

7 (2.4)

*Denotes a non-standard Phase transition
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Table 3
Cancer Types
Cancer Types

N (%)

Breast

55 (36)

Liquid

19 (12)

Prostate

16 (11)

Lung

16 (11)

Head and Neck

10 (7)

Gynecological

8 (5)

Colorectal

7 (4)

Other

21 (14)
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Table 4
Treatment Demographics
Treatment Demographics

N (%)

Surgery only

20 (13)

Chemotherapy only

14 (9)

Radiation Only

5 (3)

Surgery and Chemotherapy Only

40 (26)

Surgery and Radiation Only

27 (18)

Chemotherapy and Radiation Only
Surgery, Chemotherapy, and Radiation
No treatment
Average Months Since Treatment

5 (3)
39 (27)
2 (1)
10

Table 5
Cancer Stage
Cancer Stage

N (%)

I

37 (24)

II

39 (26)

III

37 (24)

IV

21 (14)

Unknown/not staged

18 (12)
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Changes in Peak Volume of Oxygen Consumption,
Muscular Strength, and Fatigue
in Phase Transitions
Table 6 depicts absolute values (pre-to-post) for all Phase transitions for VO2peak
(mL·kg-1·min-1), leg press muscular strength (MS) (kgs lifted), chest press MS (kgs
lifted), leg press strength-to-weight ratio (SWR), chest press SWR, and fatigue. Figure 3
depicts mean percent change in VO2peak and fatigue in each Phase transition. Figures 4
and 5 depict mean percent changes in lower and upper body strength, respectively.
Phase 1 to 2 Transition
Significant improvements were observed in VO2peak (mL·kg-1·min-1) (19.9 ± 7.5 to
22.5 ± 8.0; p < 0.001), leg press MS (kgs) (82 ± 34 to 88 ± 44; p < 0.05), chest press MS
(kgs) (27 ± 16 to 32 ± 19; p < 0.001), leg press SWR (0.98 ± 0.5 to 1.11 ± 0.5; p < 0.05),
chest press SWR (0.35 ± 0.2 to 0.38 ± 0.2; p < 0.05), and fatigue (5.0 ± 2.5 to 3.6 ± 2.0; p
< 0.05). Percent change for each variable was as follows: VO2peak (12.5%), leg press MS
(7.5%), chest press MS (16.2%), leg press SWR (9.6%), chest press SWR (8.1%), and
fatigue (-27.3%).
Phase 2 to 3 Transition
Significant improvements were observed in VO2peak (mL·kg-1·min-1) (21.1 ± 7.0 to
24.3 ± 8.4; p < 0.001), leg press MS (kgs) (83 ± 32 to 96 ± 42; p < 0.001), chest press MS
(kgs) (30 ± 18 to 36 ± 19; p < 0.001), leg press SWR (1.02 ± 0.3 to 1.18 ± 0.4; p <
0.001), chest press SWR (0.36 ± 0.2 to 0.45± 0.2; p < 0.001), and fatigue (4.2 ± 2.3 to 3.0
± 2.2; p < 0.001). Percent change for each variable was as follows: VO2peak (15%), leg
press MS (15.7%), chest press MS (23%), leg press SWR (15.7%), chest press SWR
(24.7%), and fatigue (-26.8%).
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Phase 3 to 4 Transition
Significant improvements were observed in VO2peak (mL·kg-1·min-1) (24.3 ± 7.0 to
25.5 ± 7.1; p < 0.05), chest press MS (kgs) (37 ± 18 to 40 ± 20; p < 0.05), and chest press
SWR (0.46 ± 0.2 to 0.49 ± 0.2; p < 0.05). Non-significant improvements (p > 0.05) were
observed in leg press MS (kgs) (101 ± 47 to 105 ± 41) and fatigue (3.4 ± 2.1 to 3.1 ± 2.2).
A non-significant decrease in leg press SWR was observed (1.29 ± 0.4 to 1.28 ± 0.4).
Percent change for each variable was as follows: VO2peak (5%), leg press MS (3.6%),
chest press MS (7.6%), leg press SWR (-0.1%), chest press SWR (7.6%), and fatigue (8%).
Phase 4 to 4 Transition
Non-significant improvements were observed in leg press MS (kgs) (97 ± 44 to
98 ± 37), chest press MS (kgs) (32 ± 17 to 34 ± 15), leg press SWR (1.16 ± 0.4 to 1.22 ±
0.4), and fatigue (2.8 ± 2.1 to 2.2 ± 2.0). A non-significant decrease (p > 0.05) in chest
SWR (0.44 ± 0.2 to 0.43 ± 0.2) and VO2peak (25.6 ± 6.8 to 24.6 ± 6.1) was observed.
Percent change for each variable was as follows: VO2peak (-3.6%), leg press MS (1.4%),
chest press MS (4%), leg press SWR (5.3%), chest press SWR (-2.4%), and fatigue
(-21.9%).
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Percent Change in VO2peak and Fatigue
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Figure 3. Mean percent change in VO2peak (mL·kg-1·min-1) and fatigue. *p < 0.05; †p <
0.001

Percent Change in Lower Body Strength
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Figure 4. Mean percent change in lower body strength. LP, leg press; SWR, strength-toweight ratio; *p < 0.05; †p < 0.001
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Percent Change in Upper Body Strength
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Figure 5. Mean percent change in upper body strength. CP, chest press; SWR, strengthto-weight ratio *p < 0.05; †p < 0.001

Table 6
Improvements in Physiological Values and Fatigue
Phase
Transition

Phase 1 to 2

Phase 2 to 3

Phase 3 to 4

Phase 4 to 4

43

126

68

19

N
Pre

Post

Pre

Post

Pre

Post

Pre

Post

19.9 ± 7.5

22.5 ± 8.0†

21.1 ± 7.0

24.3 ± 8.4†

24.3 ± 7.0

25.5 ± 7.1*

25.6 ± 6.8

24.6 ± 6.1

Leg press MS

82 ± 34

88 ± 44*

83 ± 32

96 ± 42†

101 ±47

105 ± 41

97 ± 44

98 ± 37

Chest Press
MS

27 ± 16

32 ± 19†

30 ± 18

36 ± 19†

37 ± 18

40 ± 20*

32 ± 17

34 ± 15

Leg Press
SWR

0.98 ± 0.5

1.11 ± 0.5*

1.02 ± 0.3

1.18 ± 0.4†

1.29 ± 0.4

1.28 ± 0.4

1.16 ± 0.4

1.22 ± 0.4

Chest Press
SWR

0.35 ± 0.2

0.38 ± 0.2*

0.36 ± 0.2

0.45 ± 0.2†

0.46 ± 0.2

0.49 ± 0.2*

0.44 ± 0.2

0.43 ± 0.2

Fatigue

5.0 ± 2.5

3.6 ± 2.0*

4.2 ± 2.3

3.0 ± 2.2†

3.4 ± 2.1

3.1 ± 2.2

2.8 ± 2.1

2.2 ± 2.0

VO2peak

Note. N = number of participants, VO2peak = peak volume of oxygen consumption (mL·kg-1·min-1); MS = muscular strength (kgs lifted); SWR =
Strength-to-weight ratio; * denotes a p value < 0.05 between pre and post values; † denotes a p value < 0.001.
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Changes in Patients Who Completed the
Entire Phase Training Model
(Entry to Phase 4)
Changes in VO2peak for patients who completed the entire Phase Model are
depicted in Figure 6. Mean initial VO2peak values at the initial assessment was 18.9
mL•kg-1•min-1. At the first reassessment, VO2peak increased to 21.7 mL•kg-1•min-1
(+15.2%). At the second reassessment, VO2peak increased to 22.5 mL•kg-1•min-1
(+3.7%). At the third reassessment, VO2peak increased to 24.4 mL•kg-1•min-1 (+8.4%).
For comparison, Figure 7 depicts mean changes in VO2peak for patients who completed
three reassessments in the previous program. Mean percent improvements for chest press
and leg press were 79.7% and 50.3%, respectively. Fatigue decreased by -29.4% from
entry to program completion.
Comparison of Patients Who Completed the
Entire Phase Training Model to
the Previous Program
Percent changes in VO2peak in the previous cancer rehabilitation program
compared to the Phase Model are depicted in Figure 8. At three months post initial
assessment, VO2peak improved by 12.1% and 15.2% for the previous program and Phase
Model, respectively. At six months post the initial assessment, VO2peak improved by
3.5% and 3.7% for the previous program and the Phase Model, respectively. At nine
months post initial assessment, VO2peak decreased by -1.1% for the older model, while
VO2peak increased by 8.4% for the Phase Model.
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Changes in VO2peak for Patients Who
Completed the Entire Phase Model
VO2peak (mL•kg-1•min-1 )
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Figure 6. Mean changes in VO2peak for patients who completed the entire Phase Model.
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Figure 7. Mean changes in VO2peak for patients who completed three reassessments in the
previous program.
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Previous Program vs Phase Model
Improvements in VO2peak
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30.0%

Percent Change
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Figure 8. Mean percent change in VO2peak: previous program vs. Phase Training Model.
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CHAPTER V

MANUSCRIPT
Abstract
Brown, J.M., Shackelford, D.Y.K., & Hayward, R. (2016). Evaluation of the Phase
Training Model of Cancer Rehabilitation. Journal of Clinical Oncology.

Exercise is a well-established method of alleviating cancer-related toxicities
during and following treatment in cancer survivors. Due to this clear evidence, exercisebased rehabilitation programs have begun to emerge. Of concern, specific
recommendations of exercise prescription for patients at different time points on the
cancer continuum have not been developed, and available guidelines are broad and
unclear. The Phase Training Model of cancer rehabilitation was created to address this
issue. Purpose: To evaluate the effects of the Phase Training Model on
cardiorespiratory endurance, muscular strength (MS), and cancer-related fatigue (CRF) in
cancer survivors during the transition from each Phase and in those who have completed
the entire Phase Training Model. Methods: A total of 152 cancer survivors’ data were
utilized. The Phase Training Model consists of four sequential Phases representing
differing time points from treatment. The designated Phase prescribes intensity,
progression, and goals unique to each. Changes in peak volume of oxygen consumption
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(VO2peak), chest press MS, leg press MS, and CRF were observed from transitions from
Phase 1 to 2, Phase 2 to 3, and Phase 3 to 4. Results: VO2peak, chest press MS, leg press
MS, and CRF all significantly improved from Phase 1 to Phase 2, and from Phase 2 to
Phase 3 (p < 0.05). VO2peak and chest press MS significantly improved in patients
transitioning from Phase 3 to 4 (p < 0.05). Conclusion: These findings suggest the Phase
Training Model provides the first clear and reproducible guidelines for exercise
prescription in cancer survivors. This exercise-based intervention yielded significant
physiological and psychological improvements in patients both during and immediately
following treatment, with reduced results as time from treatment increases.
Keywords: cancer, cancer rehabilitation, oncology rehabilitation, exercise-based
interventions
Introduction
Advancements in cancer treatments such as chemotherapy and radiation have
increased survival rates, but often result in many deleterious side-effects during and
following treatments. Cancer survivors can suffer from physiological toxicities affecting
the following systems: cardiovascular, pulmonary, musculoskeletal, immune,
gastrointestinal, hepatic, and neuroendocrine (Schneider et al., 2003; Schneider et al.,
2002). Additionally, many survivors will experience psychological decrements such as
increased fatigue (Daniell, 2004; Stone & Minton, 2008; Wu & McSweeney, 2007),
increased depression (Dauchy et al., 2013; Gagliese et al., 2007; Ng et al., 2011), and
decreased quality of life (QOL) (Lee et al., 2010; Rauma et al., 2015). Advances in
detection, diagnosis, and treatments have improved prognosis and lessened the need for
hospital and physician-based interventions (Alfano et al., 2012). Exercise-based
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programs are a viable option of cancer rehabilitation for cancer survivors as the benefits
of exercise directly attenuate the toxicities and decrements of cancer and concurrent
treatments (Dittus et al., 2015; Schmitz et al., 2010; Schneider et al., 2002).
Exercise-based interventions should be comprehensive and address the
multidimensional needs of cancer survivors during treatment and following treatment.
For this reason, a “one size fits all” approach to exercise interventions will not suffice
(Marcus et al., 2000), and survivors need prescriptive exercise that is specialized for each
individual based on treatment status and placement on the cancer continuum. There are
many different modes and intensities that are being used for physical activity-based
interventions in the cancer population, and most are unstructured. However, most
exercise programs to date have failed to properly apply and adhere to the principles of
exercise training: individuality, specificity, progression and overload (referred to as
progressive overload), reversibility, and diminishing returns (Campbell et al., 2012;
Kenney et al., 2015). Furthermore, it is currently unclear how to alter exercise
prescriptions for patients at different time points on the cancer continuum, as well as why
or when to modify exercise dosage during an intervention to elicit specific adaptations.
To date, there is only one longstanding model of a standardized exercise
intervention with guidelines for intensity, frequency, and duration for cancer survivors
(Schneider et al., 2003; Schneider et al., 2002). However, further analysis of this
program suggests reduced improvements with continued exercise, while physical
functioning remains well below average (Brown, Lalonde, et al., 2012). It was concluded
that this prescriptive exercise intervention was sufficient to improve cancer survivor’s
physiological function at the onset, but suggested that survivors may begin to experience
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diminishing returns from exercise training as the program lengthened. For those working
with cancer survivors, greater attention should be paid to the principles of exercise
training, specifically progression and overload to ensure that these individuals continue to
improve and reach apparently healthy status. The University of Northern Colorado
Cancer Rehabilitation Institute (UNCCRI) Phase Training Model of cancer rehabilitation
was created to address these concerns and provide a clear method of exercise prescription
and intervention to alleviate treatment-related toxicities. Therefore, the purpose of this
study was to evaluate the effectiveness of the Phase Training Model on cardiovascular
endurance, muscular strength, and fatigue.
Methods
Subjects
Data were obtained from patients participating in the UNCCRI cancer
rehabilitation program between the years 2012-2016. Participants were male and female
cancer survivors over 18 years of age who were undergoing or had completed surgical
intervention, chemotherapy, radiation therapy, immunotherapy, hormonal therapy, and/or
other types of unconventional treatment. All cancer survivors were cleared to participate
in an exercise program through a referral completed by his/her oncologist or physician,
and a detailed medical and cancer history for each participant accompanied each referral.
All protocols used for the study were approved by the University of Northern Colorado’s
(UNC) Institutional Review Board, and an Informed Consent was signed by all
participants.
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Experimental Design
All participants’ data were obtained from initial assessments and subsequent
reassessments. The Phase Training Model of cancer rehabilitation utilized a four Phase
approach with assessments of physiological and psychological variables conducted at
each assessment. Participants performed initial assessments upon entering the program
and completed reassessments every 12 weeks until four reassessments had been
completed. Each reassessment marked the completion of the Phase and subsequent entry
into the next. Entry into the program depended on the patients’ treatments statuses
(allowing entry as Phase 1 or Phase 2), and thus altered the length of program
completion. Phases 1 through 3 are considered “true cancer rehabilitation”, and the
program was marked as completed once the patient had entered Phase 4. However,
continued reassessments took place as patients continue the Phase Training Model in
Phase 4 and was referred to as personal training. Patients who entered the program as
Phase 1 completed the program in 36 weeks, while those who entered as Phase 2
completed the program in 24 weeks. All procedures, assessments, and measurements
were conducted by trained Cancer Exercise Specialists (CES) and overseen by the
UNCCRI Clinical Coordinator.
Preliminary Paperwork
and Patient Screening
Following participant referral and signing of the informed consent (Appendix A),
each subject was asked to complete questionnaires evaluating psychological functioning,
lifestyle, behavior, and medical information. The questionnaires included a Medical
History (Appendix D) and the Revised Piper Fatigue Scale (Appendix E). All
questionnaires were completed prior to assessment.
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Lifestyle/ activity evaluation. This questionnaire evaluated the participants’
personal lifestyle choices regarding smoking, drinking, sleep, physical activity, and diet.
Medical history. Participants’ medical information was obtained via a selfreported worksheet detailing present medical history, family medical history,
medications, allergies, and cancer diagnosis. For accuracy, medical information was also
requested from the participants’ oncologist or primary care physician at the time of
referral.
Revised Piper Fatigue Scale. Fatigue was measured via the Piper Fatigue
Inventory, which evaluates total cancer-related fatigue, as well as subscales of fatigue
such as affective, behavior, cognitive, mood, and sensory. These individual subscales
comprise 22 points with the average score representing total fatigue. The scale ranges
from 0 to 10. A score of 0 indicates that the participant shows no sign of fatigue, a score
from 1 to 3 indicates mild fatigue, 4 to 6 indicates moderate fatigue, and a score of ≥7
indicates severe fatigue (Piper et al, 1998).
Prior to the initial assessment and each subsequent reassessment, a detailed
medical and cancer screening was recorded on the Client Summary form (see Appendix
H). The Client Summary listed all pertinent cancer information, treatments, surgeries,
medications, current health status, and personal patient goals.
Phase Training Model:
Assessment Protocols
Initial assessments occurred prior to the creation of the exercise prescription and
exercise intervention. Reassessments occurred after each 12-week exercise intervention
and every 12 weeks until four consecutive reassessments had been completed. Each
assessment included the measurement of vitals, body composition, functional
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assessments, balance, pulmonary function, cardiovascular endurance, muscular strength
and endurance, and flexibility and range of motion (ROM). Results from the assessment
protocols were recorded on the Data Collection Sheet for the corresponding Phase (see
Appendices I-K).
Vital measurements. Prior to any exercise testing and throughout all physical
activity, participants’ heart rate, oxygen saturation (SPO2), and blood pressure were
assessed via a heart rate monitor with chest strap (Polar, Inc. Lake Success, NY), pulse
oximeter, and sphygmomanometer and stethoscope, respectively.
Cardiovascular endurance assessment. Cardiovascular endurance was
evaluated using the cancer-specific UNCCRI Treadmill Protocol which yields VO2peak
values. This test was found to be the most accurate and appropriate protocol for the
cancer population (Shackelford, 2015). The goal of this test was for the participant to
reach self-perceived maximal exertion or fatigue. The highest measurement of oxygen
consumption was calculated. This protocol consisted of one minute stages, which
increase speed and/or incline at the conclusion of every stage. During the test, heart rate
(HR) and oxygen saturation (SPO2) were collected at the end of every minute. Blood
pressure (BP) was recorded at the end of every three minutes, as well as the participant’s
rating of perceived exertion (RPE) on the modified Borg Scale. This RPE scale consisted
of numbers 0-10 which correlates to the perceived intensity of the test. A RPE of 0
correlated with the intensity of a stroll in the park, and a RPE of 10 signifies the patient
has reached his or her maximal effort and cannot continue. The use of handrails was
discouraged, but was allowed if deemed necessary. Handrail usage stayed consistent
throughout the test for each subject. Termination criteria of the test was: participant
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reached volitional fatigue or asked to stop for any reason, failure to increase systolic BP
or HR with increased intensity, fluctuation of more than 10 mmHg from resting measures
of diastolic BP, or an oxygen saturation that dropped below 80%. Once the protocol
ended, each subject completed a cool-down period, where all of the aforementioned
variables were measured in the same manner as during the test. Final treadmill time, BP,
HR, and RPE were recorded. Peak volume of oxygen consumption was estimated using
ACSM’s walking and running equations, which have been found to be valid in
determining VO2peak in cancer survivors (Shackelford, 2015).
Muscular strength assessment. Muscular strength was assessed via the
estimated one-repetition maximum protocol (EST 1-RM) using the Brzycki equation
(Brzycki, 1993). This test used Cybex Eagle resistance machines (Cybex Inc., Medway,
MA.) and specifically utilized the following machines: chest press, lat pulldown, seated
row, shoulder press, leg press, leg curl, and leg extension. The goal of this test was to
have the participant lift as much weight as possible between one and ten repetitions. RPE
values were asked at the end of every set. The test was performed in six steps. (1)
Before the participant began the test, the CES demonstrated how to perform each
machine correctly with proper form, and adjusted the machine to ensure a proper fit for
each participant. (2) The participant was then asked to perform a warm-up set, which
consisted of five repetitions at a low intensity. (3) After the warm-up set, the weight was
increased accordingly to elicit muscular failure or fatigue between 1 and 10 repetitions.
(4) The participant then attempted to lift the weight deemed appropriate to elicit failure
between 1 to 10 repetitions. (5) If the weight appeared to be too light to elicit failure
between 1 to 10 repetitions, the set was stopped immediately and the weight increased. If

73

the weight was too heavy for one full repetition, the weight was reduced accordingly. (6)
Finally, after a 2 to 3 minute rest, steps 4 and 5 may have been repeated up to two times
per machine to elicit a weight that resulted in muscular fatigue between 1 and 10
repetitions. The EST 1-RM values, as kgs lifted, were recorded for each machine. Leg
and chest press values were then divided by the patient’s body weight, both in kgs, to
yield a strength-to-weight ratio for each machine.
Phase Training Model:
Exercise Prescription
Exercise prescription took place following the assessment and was created using
the Client Overview document (see Appendix L). The Client Overview indicated the
Phase the participant was stratified into, the starting target intensity of both the aerobic
and resistance training components of the program, and the rate of progressive overload
prescribed during the 12 weeks for each subject. The participant screening, which was
recorded on the Client Summary, and the data collected from each assessment protocol,
which was recorded on the Data Collection Sheet, were used together to create the
exercise prescription for each participant. Specifically, the treatment status (during
versus following) and the types of treatment received dictated the Phase the participant
entered the program. If the subject was currently undergoing chemotherapy and/or
radiation therapy, he or she was placed in Phase 1. If treatment had ended prior to entry
into the program or if the subject underwent surgical intervention and/or other treatments
(hormonal, immune, etc.), he or she was placed in Phase 2. The assessment results and
specifically the classifications achieved by the participant during each assessment were
utilized to begin the process of selecting the appropriate target intensity of the
intervention. For example, if the subject performed very poorly on the UNCCRI
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Treadmill Protocol and yielded a classification of low in cardiovascular function when
compared to other cancer survivors, this indicated a prescription at the lowest end of the
Phase recommendations for HRR was needed. Likewise, if a subject performed well on
the EST 1-RM protocol and achieved a strength-to-weight ratio that indicated an above
average ranking, the resistance training intensities at the higher end of the range
recommended by the Phase were prescribed. The Client Summary further assisted the
prescription of intensity as the principle of individualization and specificity were utilized
in relation to each patient’s specific goals and desired outcomes from the program. If a
participant’s goal consisted of being able to walk or jog a 5-K race at the conclusion of
12 weeks, and if the medical history indicated this would not jeopardize the patient’s
immune function, then a steeper progression of intensity during the aerobic intervention
was prescribed. Similarly, if a participant’s goals included competing in a weight lifting
competition as part of the local Senior Games, a prescription utilizing more assertive
progressive overload was included during resistance training. The Client Overview
ensured that both essential components of exercise prescription were included,
assessment results and adherence to the principles of exercise training.
The Phase Training Model:
Exercise Intervention
Each exercise intervention session took place at UNCCRI. Physiological data
were recorded by UNCCRI CES’s. The Phase Training Model assured that the five basic
principles of exercise were being met. The main principles included progressive
overload, individuality, specificity, diminishing returns, and reversibility. The intensity
of the exercise intervention was dictated by the exercise prescription and was dependent
upon treatment status, assessment results, and ascribed Phase. A graphic representation
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of the Phase Training Model can be seen in Figure 9. One-on-one training occurred in
the first three Phases, with the option also being available in Phase 4. For all one-on-one
sessions, a whole body exercise intervention was utilized. The frequency of training was
prescribed as three sessions per week for 12 weeks. The duration of each exercise
session was 60 minutes with 20 minutes designated for cardiovascular exercise, 30
minutes for resistance exercise, 10 minutes for flexibility training, and balance exercises
incorporated throughout the entire session. The following modes were utilized for the
aerobic portion of the exercise session: treadmill, cycle ergometer, NuStep, Aquaciser
(underwater treadmill), outdoor walking or jogging. In regards to resistance exercise,
each session targeted the following muscle groups: chest (pectoralis major and minor),
back (rhomboids and latissimus dorsi), lower body (quadriceps and hamstrings), and core
(trunk stabilizers and pelvic floor), and utilized three sets of 10 repetitions of each
exercise. Other muscle groups may have been included (deltoids, biceps, triceps,
adductors, etc.) within the 30 minutes of strength training. Modes of resistance training
included: Cybex® resistance machines, therabands, dumbbells, medicine balls, body
weight, and resistance tubing.
The flexibility portion utilized stretches targeting all muscle groups that were
used during the exercise session. Additional equipment that aids in the stretching portion
included: rope pulleys, range of motion wheels, and ropes. For the addition of balance,
the following equipment was used: ski poles, stability balls, Bosu balls, Ballast balls,
dyna disks, wobble boards, and foam pads. Prior to the start of each exercise session,
resting HR, BP, and SPO2 were measured and current health was assessed via discussion
with the participant. A heart rate monitor was worn throughout the entire session by the

76

participant. At the conclusion of every session, HR, BP, and SPO2 were measured to
ensure values were near resting measures and the participant was safe to leave the
facility.

Figure 9. Phase Training Model of Cancer Rehabilitation
Phase 1 was designed for cancer survivors who are still receiving chemotherapy
or radiation treatments. Due to side effects being more prevalent while in treatment as
opposed to out of treatment (Sprod et al., 2011), the goal of this Phase was to maintain or
slightly increase a cancer survivor’s physiological and psychological values. Phase 1 was

77

specifically designed to adhere to the principles of individuality and specificity.
Decrements below baseline should not have occurred, as this Phase was designed to
attenuate the toxicities from cancer treatment. The starting intensity was categorized as
low (Kuehl et al., 2015; Schneider et al., 2003) with starting intensity ranging between
30-45% HRR and EST 1-RM. This intensity was determined by reviewing over 100
exercise logbooks from clients that were currently undergoing treatment. The mean
training intensity was well tolerated among patients and varied between 30-45% HRR,
which corresponded with intensities for those in poor health (Schneider et al., 2003).
Participants remained in this Phase for the duration of his or her cancer treatment or for
12 weeks, if treatment concluded prior to the entry into the next Phase. Of note, usage of
any aquatic exercises was prohibited during this Phase due to skin irritation resulting
from treatment.
Phase 2 was designed for cancer survivors who have moved from Phase 1 to
Phase 2, or for any survivor who had undergone cancer treatment that was not
categorized as chemotherapy or radiation therapy. Other forms of treatment included
hormonal altering or blocking therapy, immunotherapy, or stem cell transplants. Side
effects from a survivor undergoing chemotherapy or radiation differ from the side effects
experienced during other forms of treatment which are generally less severe (Collins et
al., 2011). Due to this, the starting intensity of Phase 2 was prescribed as low-tomoderate (Kuehl et al., 2015); and ranged between 40%-60% HRR and EST 1-RM. The
intensity was determined by reviewing over 100 exercise logbooks for those who had just
completed cancer treatments. This intensity range was closely related to intensities
previously reported for the active, cancer patient (Schneider et al., 2002). The goal of
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Phase 2 was to build a foundational base using corrective and functional training with a
focus on developing and stabilizing the core, pelvic floor, shoulder girdle, or any other
joints or muscles affected by surgery and/or hormonal treatments, and to alleviate the
lasting effects from chemotherapy or radiotherapy. Stabilizer muscles such as the core,
pelvic floor, and shoulder girdle are prominently affected by cancer and its treatments
(Collins et al., 2011; Swenson et al., 2002). Strengthening these components of the body
will assist with activities of daily living and general movement patterns. Phase 2 was
designed to continue adherence to the principles of individuality and specificity, and to
begin incorporating progressive overload based on assessment results and treatment
deficits. Typically, a client remained in this Phase for 12 weeks.
Phase 3 was intended for cancer survivors who have completed Phase 2, and was
the transitional Phase from cancer rehabilitation to apparently healthy exercise. As Phase
3 represented the last Phase considered cancer rehabilitation, a major goal was to educate
participants with the skills necessary to implement and maintain an exercise program on
their own. Participants should have transitioned from Phase 3 with the ability to perform
exercises with self-efficacy and knowledge to avoid injury and create progression. This
goal existed to support the principles of diminishing returns and reversibility. Phase 3
also aimed to improve physiological and psychological values beyond baselines and to
incorporate the principle of progressive overload to the highest extent. Improvements
should have occurred in cardiovascular fitness, muscular strength and endurance,
pulmonary function, flexibility, and balance. Psychological improvements should have
been visible via QOL, depression, and fatigue scores. At completion, cancer survivors
should have achieved classification near or at apparently healthy status. This type of
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training was classified as moderate-to-high, as starting intensities ranged between 6085% HRR and EST 1-RM. This range has been deemed appropriate for vigorous
exercise (Kuehl et al., 2015; Scharhag-Rosenberger et al., 2015) and overload. A cancer
survivor remained in this Phase for 12 weeks.
Phase 4 was designed for cancer survivors who have completed Phase 3, and there
was no time limit for this Phase. Cancer survivors in this Phase had successfully
completed the prior three Phases, and were deemed close or at apparently healthy status.
Phase 4 was not considered cancer rehabilitation as it was meant to assist patients for the
rest of their lives in maintaining physical activity and healthy function. Unlike the other
three Phases, additional alternatives to one-on-one training were available. Patients may
have chosen to participate in group fitness classes or attend an open gym schedule at
UNCCRI. The goal of this Phase was to maintain improvements in both physiological
and psychological values gained during the past Phases or continue progressive overload
based on the patient’s personal goals. The type of training was classified as moderate-tonear-maximal, as the range starting of intensities was 65-95% HRR and EST 1-RM. This
intensity range was appropriate for cancer survivors who are or close to apparently
healthy status (Kuehl et al., 2015; Scharhag-Rosenberger et al., 2015).
Statistical Analysis
Individual paired-sample t-tests were utilized to examine if significant differences
occurred in cardiovascular endurance, muscular strength, and fatigue during each Phase
transition. The following dependent variables were assessed: VO2peak, EST 1-RM of the
leg press, EST 1-RM of the chest press, strength-to-weight ratio for the leg press,
strength-to-weight ratio for the chest press, and fatigue. The following Phase transitions
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(assessment and reassessment) were evaluated: Phase 1 to Phase 2, Phase 2 to Phase 3,
and Phase 3 to Phase 4. Because several paired t-tests were utilized, a Bonferroni
adjustment was used to reduce the chance of committing type I error. Statistical analyses
were performed using the Statistical Package for the Social Sciences software package
(SPSS, Chicago, IL.). Significance levels were set at p < 0.05.
Results
The purpose of this study was to evaluate the effects of the Phase Training Model
on cardiorespiratory endurance, muscular strength, and cancer-related fatigue in cancer
survivors during the transition from each Phase and in those who have completed the
entire Phase Training Model.
Participant Characteristics
Table 7 displays the demographic characteristics of the participants. A total of
152 cancer survivors were included in this study. The study consisted of 58 males and 94
females, where the mean age was 62 ± 12 years of age and the mean weight was 80 ± 21
kgs. Table 8 depicts the total number of assessments and Phase transitions that occurred
among the participants. Of these, 87.7% of the assessments represented standard Phase
transitions from one Phase to the subsequent Phase, whereas 12.3% were non-standard
transitions in which the individual remained in the same Phase for an additional 12
weeks. Non-standard Phase transitions occurred from Phase 1 to Phase 1 during
continued chemotherapy and/or radiation treatment, from Phase 2 to Phase 2 when there
existed lasting functional and postural deviations that required additional time to
attenuate, and from Phase 3 to Phase 3 due to a participant that required further education
and motivation to learn proper form, exercise creation, and generate the self-efficacy
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needed to establish an exercise intervention. Tables 9, 10, and 11 display the cancer
types, treatment demographics, and cancer stages, respectively. Cancer types included:
Breast (36%), liquid (12%), prostate (11%), lung (11%), head and neck (7%),
gynecological (5%), colorectal (4%), and other cancer types (14%). Of the participants,
13% had surgery only, 9% had chemotherapy only, 3% had radiation only, 26% had
surgery and chemotherapy only, 18% had surgery and radiation only, 3% had
chemotherapy and radiation only, 27% had surgery, chemotherapy, and radiation, and 1%
had no treatment. For those who had completed treatment, the average time post
treatment was 10 months. Of the participants, 24%, 26%, 24%, and 14% were diagnosed
as stage 1, 2, 3, or 4, respectively; 12% of the stages were either unknown or were not
staged.
Mean attendance of all subjects participating in the program was 80% and average
retention was approximately 58% between each Phase Transition until program
completion. The retention for those who began in and completed Phase 1 was 54%. For
those who entered the program as Phase 2, the retention was 65%. Finally, retention for
those who completed Phase 3 and completed the program into Phase 4 was 54%. Of the
152 program participants, 33 completed the entire Phase program from entry to Phase 4.
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Table 7
Participant Characteristics
Participant Characteristics

N = 152

Age (years)

62 ± 12

Male, n (%)

58 (38)

Female, n (%)

94 (62)

Height (centimeters)

168 ± 10

Weight (kilograms)

80 ± 21

Table 8
Assessments and Phase Transitions
Phase Transitions

N (%)

Total Assessments

292

Phase 1 to Phase 2

43 (14.7)

Phase 2 to Phase 3

126 (43.2)

Phase 3 to Phase 4

68 (23.3)

Phase 4 to Phase 4

19 (6.5)

Phase 1 to Phase 1*

16 (5.5)

Phase 2 to Phase 2*

13 (4.5)

Phase 3 to Phase 3*

7 (2.4)

*Denotes a non-standard Phase Transition
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Table 9
Cancer Types
Cancer Types

N (%)

Breast

55 (36)

Liquid

19 (12)

Prostate

16 (11)

Lung

16 (11)

Head and Neck

10 (7)

Gynecological

8 (5)

Colorectal

7 (4)

Other

21 (14)
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Table 10
Treatment Demographics
Treatment Demographics

N (%)

Surgery only

20 (13)

Chemotherapy only

14 (9)

Radiation Only

5 (3)

Surgery and Chemotherapy Only

40 (26)

Surgery and Radiation Only

27 (18)

Chemotherapy and Radiation Only
Surgery, Chemotherapy, and Radiation
No treatment
Average Months Since Treatment

5 (3)
39 (27)
2 (1)
10

Table 11
Cancer Stage
Cancer Stage

N (%)

I

37 (24)

II

39 (26)

III

37 (24)

IV

21 (14)

Unknown/not staged

18 (12)
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Changes in Peak Volume of Oxygen
Consumption, Muscular Strength,
and Fatigue in Phase Transitions
Table 12 depicts absolute values (pre-to-post) for all Phase transitions for VO2peak
(mL·kg-1·min-1), leg press muscular strength (MS) (kgs lifted), chest press MS, leg press
strength-to-weight ratio (SWR), chest press SWR, and fatigue. Figure 10 depicts mean
percent change in VO2peak and fatigue. Figure 11 and 12 depicts mean percent changes in
lower body and upper body strength, respectively.
Phase 1 to 2 transition. Significant improvements were observed in VO2peak
(mL·kg-1·min-1) (19.9 ± 7.5 to 22.5 ± 8.0; p < 0.001), leg press MS (kgs) (82 ± 34 to 88 ±
44; p < 0.05), chest press MS (kgs) (27 ± 16 to 32 ± 19; p < 0.001), leg press SWR (0.98
± 0.5 to 1.11 ± 0.5; p < 0.05), chest press SWR (0.35 ± 0.2 to 0.38 ± 0.2; p < 0.05), and
fatigue (5.0 ± 2.5 to 3.6 ± 2.0; p < 0.05). Percent change for each variable was as
follows: VO2peak (12.5%), leg press MS (7.5%), chest press MS (16.2%), leg press SWR
(9.6%), chest press SWR (8.1%), and fatigue (-27.3%).
Phase 2 to 3 transition. Significant improvements were observed in VO2peak
(mL·kg-1·min-1) (21.1 ± 7.0 to 24.3 ± 8.4; p < 0.001), leg press MS (kgs) (83 ± 32 to 96 ±
42; p < 0.001), chest press MS (kgs) (30 ± 18 to 36 ± 19; p < 0.001), leg press SWR (1.02
± 0.3 to 1.18 ± 0.4; p < 0.001), chest press SWR (0.36 ± 0.2 to 0.45± 0.2; p < 0.001), and
fatigue (4.2 ± 2.3 to 3.0 ± 2.2; p < 0.001). Percent change for each variable was as
follows: VO2peak (15%), leg press MS (15.7%), chest press MS (23%), leg press SWR
(15.7%), chest press SWR (24.7%), and fatigue (-26.8%).
Phase 3 to 4 transition. Significant improvements were observed in VO2peak
(mL·kg-1·min-1) (24.3 ± 7.0 to 25.5 ± 7.1; p < 0.05), chest press MS (kgs) (37 ± 18 to 40
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± 20; p < 0.05), and chest press SWR (0.46 ± 0.2 to 0.49 ± 0.2; p < 0.05). Nonsignificant improvements (p > 0.05) were observed in leg press MS (kgs) (101 ± 47 to
105 ± 41) and fatigue (3.4 ± 2.1 to 3.1 ± 2.2). A non-significant decrease in leg press
SWR was observed (1.29 ± 0.4 to 1.28 ± 0.4). Percent change for each variable was as
follows: VO2peak (5%), leg press MS (3.6%), chest press MS (7.6%), leg press SWR (0.1%), chest press SWR (7.6%), and fatigue (-8%).
Phase 4 to 4 transition. Non-significant improvements were observed in leg
press MS (kgs) (97 ± 44 to 98 ± 37), chest press MS (kgs) (32 ± 17 to 34 ± 15), leg press
SWR (1.16 ± 0.4 to 1.22 ± 0.4), and fatigue (2.8 ± 2.1 to 2.2 ± 2.0). A non-significant
decrease (p > 0.05) in chest SWR (0.44 ± 0.2 to 0.43 ± 0.2) and VO2peak (25.6 ± 6.8 to
24.6 ± 6.1) was observed. Percent change for each variable was as follows: VO2peak (3.6%), leg press MS (1.4%), chest press MS (4%), leg press SWR (5.3%), chest press
SWR (-2.4%), and fatigue (-21.9%).
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Figure 10. Mean percent change in VO2peak and fatigue. *p < 0.05; †p < 0.001

87

Percent Change in Lower Body Strength
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Figure 11. Mean percent change in lower body strength. LP, leg press; SWR, strengthto-weight ratio; *p < 0.05; †p < 0.001
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Figure 12. Mean percent change in upper body strength. CP, chest press; SWR,
strength-to-weight ratio; *p < 0.05; †p < 0.001

Table 12
Improvements in Physiological Values and Fatigue
Phase
Transition

Phase 1 to 2

Phase 2 to 3

Phase 3 to 4

Phase 4 to 4

43

126

68

19

N
Pre

Post

Pre

Post

Pre

Post

Pre

Post

19.9 ± 7.5

22.5 ± 8.0†

21.1 ± 7.0

24.3 ± 8.4†

24.3 ± 7.0

25.5 ± 7.1*

25.6 ± 6.8

24.6 ± 6.1

Leg press MS

82 ± 34

88 ± 44*

83 ± 32

96 ± 42†

101 ±47

105 ± 41

97 ± 44

98 ± 37

Chest Press
MS

27 ± 16

32 ± 19†

30 ± 18

36 ± 19†

37 ± 18

40 ± 20*

32 ± 17

34 ± 15

Leg Press
SWR

0.98 ± 0.5

1.11 ± 0.5*

1.02 ± 0.3

1.18 ± 0.4†

1.29 ± 0.4

1.28 ± 0.4

1.16 ± 0.4

1.22 ± 0.4

Chest Press
SWR

0.35 ± 0.2

0.38 ± 0.2*

0.36 ± 0.2

0.45 ± 0.2†

0.46 ± 0.2

0.49 ± 0.2*

0.44 ± 0.2

0.43 ± 0.2

Fatigue

5.0 ± 2.5

3.6 ± 2.0*

4.2 ± 2.3

3.0 ± 2.2†

3.4 ± 2.1

3.1 ± 2.2

2.8 ± 2.1

2.2 ± 2.0

VO2peak

Note. N = number of participants, VO2peak = peak volume of oxygen consumption (mL·kg-1·min-1); MS = muscular strength (kgs lifted); SWR =
Strength-to-weight ratio; * denotes a p value < 0.05 between pre and post values; † denotes a p value < 0.001.
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Changes in Patients Who Completed
the Entire Phase Training Model
(Entry to Phase 4)
Changes in VO2peak for patients who completed the entire Phase Model are
depicted in Figure 13. Mean initial VO2peak values at the initial assessment was 18.9
mL•kg-1•min-1. At the first reassessment, VO2peak increased to 21.7 mL•kg-1•min-1
(+15.2%). At the second reassessment, VO2peak increased to 22.5 mL•kg-1•min-1
(+3.7%). At the third reassessment, VO2peak increased to 24.4 mL•kg-1•min-1 (+8.4%).
Mean percent improvements for chest press and leg press were 79.7% and 50.3%,
respectively. Fatigue decreased by -29.4% from entry to program completion.

Changes in VO2peak for Patients who
Completed the Entire Phase Model
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Figure 13. Mean changes in VO2peak for patients who completed the entire Phase Model.
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Discussion
The Phase Training model of cancer rehabilitation elicited improvements in
cardiovascular endurance, muscular strength, and/or fatigue during all Phase transitions.
The majority of significant improvements occurred during the transition from Phase 1 to
Phase 2 and from Phase 2 to Phase 3, although each specific Phase resulted in
improvements for most variables. For the patients who achieved Phase 4 and completed
the rehabilitation program, cardiovascular endurance, muscular strength, and fatigue
improved during each Phase transition, eliminating the plateau in progression that had
been observed in our previous model (Brown, Lalonde, et al., 2012). These
improvements resulted from the detailed and individualized method of exercise
prescription and progression utilized in the Phase Training model.
Phase 1
Participants who completed Phase 1 experienced significant improvements in all
variables after the 12-week intervention. The goal of Phase 1 was to maintain or offset
any negative side effects caused by treatment with low intensity, prescriptive exercise.
However, the low intensities set for this Phase not only reduced the decline in function
caused by treatment, it significantly improved function. Participants who completed
Phase 1 improved upper (16%) and lower (8%) body muscular strength, cardiovascular
endurance (13%), and fatigue (-27%). Similar improvements in upper body strength
(Adamsen et al., 2009; Jarden, Baadsgaard, Hovgaard, Boesen, & Adamsen, 2009) and
lower body strength (Adamsen et al., 2009; Battaglini et al., 2007) have been observed in
patients undergoing treatment previously. Strength training increases protein synthesis,
increases muscle mass, and may offset cancer-related cachexia. This may explain why
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survivors in Phase 1 not only maintained strength levels, but significantly improved
beyond baseline measurements. Additionally, aerobic exercise has demonstrated
cardioprotective effects which may explain the improvements observed in cardiovascular
function (Chicco, Schneider, & Hayward, 2006; Scott et al., 2011). Cancer-related
fatigue decreased by 27% in the patients transitioning from Phase 1 and this reduction is
similar to previously observed results (Puetz & Herring, 2012; Schneider et al., 2007b).
Contrary to the belief that fatigue levels may be heightened for those exercising while
undergoing treatment, this study shows that when exercising at appropriate intensities,
fatigue levels can be significantly reduced.
The improvements observed in Phase 1 exceeded expectations, as the exercise
prescription dictated a low intensity (30-45% HRR) and a small progression for
cardiovascular endurance and muscular strength of 5% and 15%, respectively. Modest
improvements were anticipated as the majority of patients underwent all major treatment
types and specifically due to the known toxicities associated with chemotherapy. Similar
results have been observed in a demographically comparable group of breast cancer
survivors undergoing treatment following a 12-week high intensity (60-100% of VO2peak)
aerobic exercise intervention (Hornsby et al., 2014). The exercise intensity prescribed in
The Phase Training model for patients in Phase 1 was low due to the J-shaped curvilinear
relationship between the risk of infection and increasing exercise workloads, where
vigorous or heavy intensity exercise may result in a higher than normal risk of infection
(Nieman, 1994). While the moderate-to-high intensity exercise utilized by Hornsby et al.
(2014) yielded significant aerobic improvements, we demonstrate that similar benefits
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occur using a lower intensity. This lower intensity may preserve immune function and
reduce the risk of adverse effects in patients undergoing treatment.
Phase 2
Energy levels have been observed to increase once treatment has been completed
(Courneya & Friedenreich, 1997). Due to this, exercise tolerance for an individual who
has completed treatment will increase and may enhance the positive effects of exercise
(Pinto, Trunzo, Reiss, & Shiu, 2002). The intensity prescribed for Phase 2 is higher than
that of Phase 1 and represents a low-to-moderate range (40-60% HRR/EST-1RM)
dependent on the patient’s improvements from the previous Phase and/or lingering
treatment side-effects. Additionally, patients in Phase 2 were prescribed up to a 20%
progression for cardiovascular improvements and between 30 to 50% for strength. In
conjunction with the increased emphasis on the principle of progressive overload, Phase
2 also prescribes correctional exercises with the goal of attenuating functional and
postural deviations that may be present in patients following treatment or surgical
intervention. This prescription and rate of progressive overload allowed the patients to
achieve greater improvements in fatigue, cardiovascular endurance, and muscular
strength than in Phase 1.
Levels of cancer-related fatigue significantly decreased in patients transitioning
from Phase 2 to Phase 3 by 27%. This reduction resulted in the improvement of fatigue
classification from “moderate” to “mild.” It has been considered that greater
improvements in fatigue will be observed in patients with a longer duration between
treatment completion and exercise program initiation. Specifically, fatigue
improvements are thought to be greater in those post treatment compared to those in
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treatment (Puetz & Herring, 2012). Our findings show that significant declines in fatigue
are possible immediately following treatment even with treatment completion averaging
only 10 months. Interestingly, these improvements in fatigue, for many patients, were
additive to the large, almost identical, significant improvements previously observed in
Phase 1, suggesting that exercise attenuates cancer-related fatigue to the greatest extent
during treatment and immediately following.
Cardiovascular endurance significantly increased by 15% in the transition from
Phase 2 to Phase 3, which is slightly greater than improvements seen previously in earlier
versions of our program (Brown, Lalonde, et al., 2012; Schneider et al., 2007b). In a
study by Dittus et al. (2015), a similar Phase 2-based, 12-week exercise program with 20
minutes of cardiovascular exercise prescribed at 70 to 85% HRmax in patients following
treatment, resulted in a 7.5% non-significant improvement in VO2peak. This smaller
improvement may have been due to utilizing a group model of four to six patients versus
an individualized, one-on-one model or due to the subject demographics. This study
consisted of mainly female breast cancer survivors, with an average time of 2.36 years
post treatment. The subjects may not accurately represent the diverse cancer and
treatment types represented in the cancer population immediately following treatment,
and thus experience reduced side effects limiting exercise-based improvements.
Muscular strength improved significantly in subjects completing Phase 2 by an
average of 20%. Similar improvements in strength have been observed in several other
studies in cancer survivors not undergoing treatment (Schneider et al., 2007b), many of
which utilized higher intensities (Dittus et al., 2015; Schneider et al., 2007b). In fact,
following a moderate-to-high intensity resistance training intervention in breast cancer
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survivors following treatment (average time from treatment of 56.5 months), average
muscular strength improved significantly by 16%. Of note, the authors stated that
strength only improved in those subjects who attended 50% or more of the prescribed
exercise sessions and that withdrawal from the program occurred primarily in those
closest to treatment (approximately 43 months since treatment) (Winters-Stone et al.,
2013).
A correlation may exist between exercise intensity, time from treatment, and
attendance. The intensities prescribed in Phase 2 are low-to-moderate and were capable
of eliciting similar improvements in strength as the higher intensity intervention used by
Winters-Stone et al. (2013). Specifically, as the average time from treatment in our study
was 10 months and represents a common time point in the cancer population immediately
following treatment, a lower than vigorous intensity may be desirable if it enhances
exercise attendance for those closest to treatment. To further this thought, although the
preservation of immune function is of less concern in those following treatment as
opposed to those in treatment, and a higher intensity may not negatively affect health,
increased exercise intensity may reduce attendance rates and adherence (Cox, Burke,
Gorely, Beilin, & Puddey, 2003). In fact, in a study of sedentary adults randomly
assigned to a moderate intensity or vigorous intensity exercise intervention, adherence
was significantly greater in the moderate intensity group (Perri et al., 2002). The low-tomoderate intensity of Phase 2 resulted in significantly improved physiological and
psychological values in cancer survivors immediately following treatment, while
maintaining an average attendance rate of 80%. This suggests that the intensity and
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progression prescribed in Phase 2 not only improves function, but may positively affect
program attendance and adherence.
Phase 3 and Phase 4
Patients who transitioned from Phase 3 to 4 significantly improved cardiovascular
endurance and upper body strength by 5% and 8%, respectively. Fatigue was reduced by
-8% and lower body strength improved by 4%, but both were not significant. The
transition from Phase 3 marks the end of true cancer rehabilitation in the Phase Training
model and while many patients remain in the program for Phase 4 training, it is rarely
individualized as most opt for a group model of exercise intervention.
Following the completion of Phase 3, 65% of the participants improved to the
“good” or above classifications for strength-to-weight ratio for the leg press. In fact, 53%
of the subjects scored in the “excellent” or “superior” classification for lower body
strength when compared to the apparently healthy norms. Forty-three percent of the
patients improved to the “good” or above classification for strength-to-weight ratio for
the chest press, and although this is lower than lower body strength improvements, it
should be noted that 36% of our patients are breast cancer survivors and that
improvement in this variable was still significant. Perhaps of greatest importance, 59%
of the cancer survivors in this study improved in cardiovascular endurance, as measured
by VO2peak, to a classification and percentile deemed “fit” (Blair et al., 1989; Farrell,
Braun, Barlow, Cheng, & Blair, 2002). It has been demonstrated that sedentary men who
were unfit at the initial examination, but who became fit at reassessment, had a 44%
reduction in risk of mortality when compared to similar unfit men who did not improve.
Specifically, for each minute increase in treadmill time, there is a corresponding 8%
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decrease in the risk of mortality (Blair, et al., 1989). Improvement by one minute
increments using the UNCCRI Treadmill protocol generates an increase in calculated
VO2peak. The Phase Training model yielded significant improvements in VO2peak during
the transition from Phases 1, 2, and 3. Notably, these consistent improvements in VO2peak
at each Phase transition can represent a reduction in all-cause mortality from entry to
completion of the program. Considering the complex treatment-related toxicities
experienced by most cancer survivors, this continual decrease in risk of mortality at each
reassessment may improve prognosis and reduce risk of recurrence. Improvements in
fatigue were minimal, but this may be expected as time from treatment is increased and
as exercise exposure increases, the severity of perceived fatigue will also decrease
(Schwartz et al., 2001).
Across all parameters, the amount of improvement was reduced in Phases 3 and 4,
when compared to the large improvements observed in Phases 1 and 2. Although
improvements were observed in all variables, only upper body strength and
cardiovascular endurance improved significantly in Phase 3. Upper and lower body
strength improved slightly in Phase 4, while VO2peak remained relatively the same.
Fatigue continued to be reduced through all Phase transitions and was the lowest for
those in Phase 4. For some individuals this reduction in improvements may be due to the
principle of diminishing returns, particularly in those who yielded classifications above
excellent. For others, there may have been an unforeseen reduction in the ability to
maintain adherence to the principle of overload as the frequency and duration of exercise
sessions were capped in this study. Phase 3 was designed to adhere to the principle of
progressive overload, as the intensity prescribed in Phase 3 represents a vigorous or high
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intensity. ACSM recommends a frequency of 5 to 7 days per week at a moderate
intensity (40-59% HRR) for 30 to 60 minutes each day. Additionally, if the exercise
intensity is vigorous (60-89% HRR), the recommended frequency is 3 to 5 days per
week, for 20 to 60 minutes each day. Phase 3 adheres to the lower end of the latter
recommendation. The program prescribes exercise for three, 60 minute sessions per
week (combined aerobic and resistance training) at a vigorous intensity of 60-85%
HRR/EST 1-RM. This level of progressive overload may be sufficient to elicit change in
some individuals in Phase 3, but as one adapts to the stress of the exercise (and the sideeffects from cancer treatments continue to lessen), the fitness level increases, and greater
volume is needed to elicit further results. The volume of exercise refers to the product of
frequency, intensity, and duration (American College of Sports Medicine, 2013). The
intensity prescribed in Phase 3 already represents a vigorous intensity, therefore to
increase progressive overload, the frequency and duration must be enhanced.
Unfortunately, the ability to increase session length or add additional sessions is limited
by program infrastructure and by cost to the patient. Therefore, volume must be
increased via frequency and/or duration outside of the program, by the patients
themselves.
The United States Department of Health and Human Services (USDHHS)
recommends a minimum of 150 minutes of moderate intensity exercise or 75 minutes of
vigorous exercise per week to obtain health benefits (U.S. Department of Health and
Human Services, 2008). Phase 3 prescribes about 150 minutes per week of vigorous
exercise to meet this guideline, however it is stated that at least twice this amount
(USDHHS), and up to five times (Sattelmair et al., 2011), is needed for additional
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benefits. In a recent study of our Phase 3 and 4 program participants documenting their
daily physical activity patterns, it was revealed that 78% of their time was spent in
sedentary behavior, 20% spent in light physical activity, and only 2% spent doing
moderate-to-vigorous exercise. It was concluded that the vigorous exercise occurred only
during the prescribed exercise sessions, and that the participants remained largely
sedentary the remainder of the week (Coronado et al., 2016). Because the majority of the
participants transitioning from Phase 3 represent “good” or “fit” classifications for
strength and aerobic capacity, an increased frequency and/or duration must be
incorporated by the individual outside of the program to continue to elicit results.
Although the education and generation of self-efficacy and intrinsic motivation is already
an established goal of Phase 3, these results suggest an imperative need to begin this
process immediately at the start of Phase 3 and during Phase 4. To accomplish this,
individuals working with cancer survivors in an exercise-based rehabilitation program
must prescribe exercise “homework” for their patients and it must be followed by the
patient outside of the established rehabilitation program to ensure continued
improvements. As stated previously, higher intensity exercise results in reduced
attendance and adherence. Therefore, while clinicians can attempt to increase intensity
further to ensure progressive overload during the intervention without relying on added
frequency or duration, it may limit attendance and ultimately result in the completion of
less exercise over time (Perri et al., 2002).
A Need for Phases 3 and 4?
The improvements observed in Phases 3 and 4 were less than those observed in
the earlier Phases. This may be due to the principle of diminishing returns and the
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continued physical improvements observed as time from treatment grows. Specifically,
for most patients who have experienced improvement in the previous Phases, increased
progressive overload in the form of increased frequency or duration outside of the
established program may be needed. Some clinicians may suggest there is no need for an
established intervention at this time point and propose the removal of Phases 3 and/or 4.
To negate this thought, it has been well-documented that home-based or homework
assigned exercise interventions have significantly lower attendance and adherence rates
when compared to supervised interventions. Specifically, Winters-Stone et al. (2013)
documented that the home-based portion of a resistance training exercise program
resulted in an attendance rate of only 27% versus 82% in the supervised sessions.
Similarly, another study examined whether six months of supervised exercise resulted in
greater long-term retention and adherence when compared to a regular, home-based
intervention in older, sedentary women. It was found that exercise adherence was
significantly higher in the supervised group and that energy expenditure was higher (Cox
et al., 2003). Although it may be tempting to limit the prescriptive, individualized
exercise intervention to Phases 1 and 2, for some individuals the intensity of Phase 3
alone may generate enough stress to elicit improvements, and for others, adoption of
additional exercise at home may be more manageable in conjunction with regularly
scheduled exercise sessions.
In recognition of the principle of individuality, not all patients completed a
standard transition from one Phase to the next. Twelve percent of our subjects reassessed
into the same Phase following the 12-week intervention, representing a non-standard
transition. The majority of these, about 16 (5.5%) patients remained in Phase 1 due to

100

continued treatment status. Thirteen (4.5%) patients experienced functional and postural
deviations as a result of surgical intervention and treatments that required additional time
to address, causing them to remain in Phase 2. Only seven subjects (2.4%) remained in
Phase 3 due to the fact that they required further education to reach the targeted level of
self-efficacy to progress to Phase 4. The Phase Training model ensures individuality is
maintained even when standard Phase transitions are not justified.
The prescribed intensity and rate of progression of Phase 1 was appropriate for
those in treatment and was well-tolerated. This addresses concerns that patients during
treatment may not be able or willing to participant in an exercise-based rehabilitation
program, and negates the thought that these patients only be prescribed in-patient
physical therapy (Dittus et al., 2015). Our results suggest that not only is our model safe,
but that it is capable of eliciting significant physiological and psychological
improvements despite the limiting side effects of treatment. We suggest that the exercise
prescription utilized in Phase 1 become the standard intervention for patients undergoing
treatment.
Conclusion
To date, this is the only study to establish a structured model of cancer
rehabilitation and to evaluate its effectiveness over a longitudinal timeframe in patients at
different time points on the cancer continuum. Research is lacking on exercise
interventions lasting longer than three months, specifically with consistent reassessment
of physiological and psychological data. The information gained from these long-term
interventions is needed to determine the effectiveness of exercise-based rehabilitation on
patient prognosis, rates of recurrence, and total healthcare costs.
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Currently, there are a limited number of exercise-based programs being offered
for cancer survivors despite the evidence that exercise rehabilitation improves functional
capacity (Brown, Huedo-Medina, et al., 2012; Dittus et al., 2015; Schmitz et al., 2010;
Schneider et al., 2007a; Winters-Stone et al., 2013), may lessen the likelihood of cancer
recurrence, and decreases mortality (Blair et al., 1989). The majority of these programs
are paid for out of pocket by the patients due to lack of insurance reimbursement and
general inadequacy of support from the medical community. Of concern, from our
experience, is that the personal financial burden of these programs directly contribute to
patient attrition and may limit the benefits gained from a long-term intervention.
This study included participants of both genders, all major cancer types, varying
treatment plans, and statuses both during, immediately following and following
treatment. Most studies suffer from an overwhelmingly biased patient demographic (e.g.
all males, only breast cancer survivors, only during treatment, non-clinically relevant
time from diagnosis, etc.). Our subject demographics represents a well-rounded view of
the cancer population and for a longer duration of intervention than any other studies.
Up to this point, specific recommendations regarding mode, intensity, frequency,
and duration of exercise for cancer survivors has been lacking. As a result, clinicians in
general have failed to adhere to the principles of exercise training which guide
appropriate exercise prescription for cancer patients. Data from this study provide the
first clear and reproducible evidence in support of the Phase Training Model for cancer
survivors. This model outlines guidelines for exercise prescription in the cancer
population and it consistently yields significant physiological and psychological
improvements in cancer survivors both during and following treatment. Based on this
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evidence, it is recommended that the Phase Training Model become the standard for
exercise-based cancer rehabilitation programs.
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